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CHAPTER 1 
INTRODUCTION 
1.1. GENERAL INTRODUCTION AND AIM OF THE STUDY 
"Asthma is a disease characterized by an increased responsiveness of 
the trachea and bronchi to various stimuli and manifested by a wide-
spread narrowing of the airways that changes in severity either spon-
taneously or as a result of therapy." 
Twenty-four years after this definition was stated by the American 
Thoracic Society (1962) it is still uncertain what the real mechanisms 
are which cause this disease· Morphological characteristics of asthma 
are hypertrophy and contraction of the bronchial smooth muscles, 
thickening of the basement membrane and edema of the airway wall with 
an infiltrate of inflammatory cells such as eosinophils and polymor-
phonuclear leucocytes (Clark and Godfrey, 1983). Furthermore, there 
may be submucosal gland hypertrophy and plugging of airways with vis-
cid secretions containing desquamated epithelial cells and eosino-
phils. These pathological changes are found throughout the airways in 
fatal cases of asthma· It is uncertain, however, whether all these 
features are present in less severe attacks of asthma. 
The pathogenesis of asthma is even more complicated and many as-
pects have not yet been elucidated. This is partly due to the fact 
that asthma is a multifactorial disease. Mechanisms which have been 
described as important in the pathogenesis of asthma include antigen-
antibody reactions with release of bronchoconstrictor mediators from 
lung mast cells and other immunoreactive cells. Dysregulation of the 
autonomic nervous system has also been postulated. Respiratory heat 
loss, disturbances in ion and water concentrations and transport 
across the airway epithelium have been mentioned as aetiological fac-
tors in asthma induced by exercise. 
Asthma, chronic obstructive bronchitis and emphysema belong to a 
group of pulmonary diseases often referred to as chronic nonspecific 
lung disease (CNSLD). This term was introduced by Orie et al. (1961) 
because these affections are often regarded as different manifesta-
tions of the same syndrome, in which the same underlying pathophysio-
logical mechanisms play a role. Moreover, patients with CNSLD may show 
various disease symptoms and transitions of the clinical picture in 
the course of life. 
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We have focused our research on the autonomic regulation of the 
lung and airways In patients with CNSLD, with emphasis on the ß-adre-
nergic system· This thesis presents studies concerning the effects of 
^-adrenergic blockade and stimulation on the lung function of patients 
with asthma and chronic obstructive bronchitis. 
It is a well-known phenomenon that 0-blockers can cause or aggra-
vate asthma. This is mainly a problem of nonselective 0-adrenoceptor 
antagonists, since 0^-adrenoceptor selective antagonists have a less 
marked bronchoconstrictor effect. Newly developed 0-adrenoceptor anta-
gonists have recently shown a high degree of 0^-adrenoceptor selecti-
vity in animal experiments. To assess the 0i-adrenoceptor selectivity 
of two new 0-blockers (bisoprolol and bevantolol) in man, their in-
fluence on bronchomotor tone and their interaction with the 02-adreno-
ceptor agonist terbutaline was studied in patients with asthma (Chap-
ters 4 and 6). 
The effects of 0-adrenoceptor-blocking agents on lung function can 
be enhanced by exercise. This phenomenon is probably caused by more 
effective ß-blockade during a state of increased sympathetic tone. 
This rise in sympathetic tone due to exercise is also suggested to be 
responsible for the increase in forced expiratory airflow which can be 
demonstrated during exercise. We studied this hypothesis by measuring 
forced expiratory airflow at rest and during and after exercise in 
asthmatic patients both during placebo and during ß-blockade (Chapter 
6). 
The influence of 0-blockers on the lung function of patients with 
CNSLD is usually assessed by means of single-dose studies. This method 
has been criticized because multiple doses of ß-blockers may have a 
more detrimental effect on the lung function of these patients. We 
therefore studied the effects of long-term treatment with metoprolol, 
a ßj-adrenoceptor selective blocker, and pindolol, a nonselective 0-
blocker with intrinsic sympathomimetic activity (ISA) in patients with 
CNSLD and concomitant hypertension. We also tried to establish whether 
the ISA of pindolol has a beneficial effect on lung function (Chapter 
5)· 
In the literature there has been discussion whether the bronchocon-
strictlon induced by 0^-adrenoceptor selective antagonists may be 
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caused by the possible presence of ßj-adrenoceptors In bronchial 
smooth muscles or by lack of selectivity of these ^-blockers. To es-
tablish whether 0^-adrenoceptors play a role in bronchoconstriction 
or bronchodilatation, we studied the effects of the partial B^-adre-
noceptor agonist xamoterol on the lung function of asthmatic patients 
(Chapter 7). 
Functionally, the airway system can be divided into central or 
large airways on the one hand and peripheral or small airways on the 
other. 
From this point of view we attempted to establish whether ß-adreno-
ceptor blocking and stimulating agents preferentially affect large or 
small airway function or induce a more generalized airway obstruction 
or dilatation respectively (Chapters 5, 6 and 8). 
Before we present these studies, a general introduction of the autono-
mic regulation of the lung is given in Chapter 2, with emphasis on the 
0-adrenergic system. Thereafter, several methods are described in 
Chapter 3, to assess the effects of 3-adrenoceptor agonists and anta-
gonists on lung function parameters of large and small airways in pa-
tients with CNSLD. 
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1.2· LIST OF ABBREVIATIONS 
BP 
cc 
CNSLD 
CV 
CV (%) 
Δ 
ДМЕРзо 
EPP 
FEV! 
FVC 
He-02 
HR 
MEFV-curve 
MEF50 
MEF25 
N2 
Ρ 
PEFR 
Raw 
RV 
SEM 
sGaw 
TLC 
V 
VC 
івоФ 
blood pressure 
closing capacity 
chronic nonspecific lung disease 
closing volume 
coefficient of variation 
change 
MEFsodte-O?) - MEFsoCair)
 χ 1 0 0 % » d e n s i t y dependence 
MEF50(air) 
equal pressure point 
forced expiratory volume in one second 
forced vital capacity 
gas mixture of 80% helium and 20% oxygen 
heart rate 
maximal expiratory flow-volume curve 
maximal expiratory flow when 50% of the FVC remains 
to be expired 
maximal expiratory flow when 25% of the FVC remains 
to be expired 
nitrogen 
pressure 
peak expiratory flow rate 
total airway resistance 
residual volume 
standard error of the mean 
specific airway conductance 
total lung capacity 
lung volume 
gas flow 
vital capacity 
volume of isoflow 
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CHAPTER 2 
THE AUTONOMIC REGULATION OF THE LUNG AND AIRWAYS 
2.1. INTRODUCTION 
The autonomic regulatory system of the lung and airways consists of 
the parasympathetic cholinergic system and the sympathetic or adrener-
gic system; a third nervous system in the lung, known as the nonadre-
nergic, nonchollnergic system, has also been described (Richardson 
and Béland, 1976; Richardson, 1979; Boushey et al, 1980; Nadel, 1980) 
(Fig. 1; next page). 
With regard to the terminology it should be mentioned that "choli-
nergic" and "adrenergic" refer to the postganglionic nerve fibres, the 
neurotransmitter in both the parasympathetic and sympathetic ganglia 
being acetylcholine. However, the neurotransmitter in the postganglio-
nic sympathetic junction at the end-organ is noradrenaline, whereas in 
the postganglionic parasympathetic junction the neurotransmitter is 
acetylcholine. 
Since dysfunction of the autonomic regulation of the airways is 
thought to be one of the causes of asthma (Boushey et al, 1980; Nadel 
and Barnes, 1984), abnormalities in the 3-adrenergic system may con-
tribute to an abnormal function of the airways of asthmatic patients. 
Otherwise, it may be that asthma by itself can induce impairment of 
the function of the 3-adrenoceptors in the airways. 
B-Adrenoceptor antagonists, for instance, can cause bronchocon-
striction in asthmatic patients (McNeill, 1964; Greefhorst, 1983) but 
not in normal subjects (Tattersfield et al, 1973; Woods et al, 1979). 
On the other hand, ß-adrenoceptor agonists have proved to be the most 
powerful bronchodilators in asthma (Barnes et al, 1984), indicating 
good reactivity of the S-adrenoceptors in the airways of asthmatic 
patients. 
In the following sections the three components of the autonomic re-
gulatory system of the lung are discussed. It should be borne in mind 
that most of the present knowledge on the function of the autonomic 
nervous system in the lung has been obtained from animal studies, and 
there is considerable variation in airway innervation In different 
species (El-Barmini and Grant, 1975; Richardson, 1979; Partanen 
et al, 1982) and even within the same species (Woolcock et al, 1969a). 
16 
sympathetic 
nerve 
adrenergic 
vagal nerve 
cholinergic-cffcrent 
NANC 
β-agonist (?) 
β-antagonist (?) 
adrenaline 
β-agonist 
ß-ontogonist 
afferent 
airway lumen 
Figure 1· Autonomic regulation of bronchial smooth muscle tone. 
A. The cholinergic system. Efferent nerve fibres synapse In choli-
nergic ganglia In the airway wall and postganglionic cholinergic 
fibres terminate on muscarinic receptors (M) with acetylcholine 
(ACh) as neurotransmitter. (Afferent fibres originating from sen-
sory receptors (S) in the airway epithelium run through the vagal 
nerve to the central nervous system.) 
B. The nonadrenerglc, nonchollnerglc system (NANC). NANC nerve fibres 
probably travel through the vagal nerves, synapse in the ganglia in 
the airway wall, and terminate on receptors in the airway smooth 
muscle, possibly with vasoactive intestinal peptide (VIP) as neuro-
transmitter. 
С The adrenergic system. Adrenaline from the adrenal medulla and 0-
adrenoceptor agonists and antagonists interact via ^ adrenoceptors 
(02) with the airway smooth muscle. Adrenergic nerve fibres origi­
nating from the sympathetic trunk ganglia, are supposed to termi­
nate on P^-adrenoceptors located on the cholinergic ganglia in the 
airway wall, with noradrenaline (NA) as neurotransmitter. Choliner­
gic nerve activity could in this way be modulated by adrenergic ac­
tivity. It Is suggested that 0-adrenoceptor agonists and antago­
nists also interact with cholinergic nerve activity via B^-and/or 
02~adrenoceptors on cholinergic ganglia or postganglionic nerves. 
(Modified after Barnes, 1984a). 
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2.2. THE CHOLINERGIC SYSTEM 
The airways are innervated by efferent cholinergic nerve fibres. Pre-
ganglionic fibres originating from the vagal nuclei travel through the 
vagal nerves to parasympathetic ganglia located in the airway wall and 
around the blood vessels. From these small ganglia postsynaptic fibres 
innervate the airway smooth muscles (Fig. 1), vasculature, submucosal 
glands and epithelium (Richardson, 1979; Nadel, 1980; Nadel and Bar-
nes, 1984). Acetylcholinesterase-containing nerve fibres have been de-
monstrated mainly from the trachea to the larger bronchioli and in 
some animals down to the terminal bronchioli (El-Bannini and Grant, 
1975; Nadel, 1980; Partanen et al, 1982). The postganglionic choliner-
gic fibres terminate on muscarinic receptors of the end-organs because 
neurotransmission can be blocked by antimuscarinic agents such as 
atropine (Nadel, 1984; Van Koppen et al, 1985). Electrical field sti-
mulation of vagal preganglionic fibres causes bronchoconstriction, 
which effect can be inhibited by atropine (Widdicombe, 1962; Richard-
son, 1979; Nadel, 1980; Vermeire and Vanhoutte, 1979). 
In normal human airways some resting bronchial tone is present, 
which is maintained by vagal nerve activity and hence can be blocked 
by atropine (Widdicombe, 1962; Nadel, 1980; Davis et al, 1982). Hyper-
activity of the cholinergic system, on the other hand, can lead to in-
creased bronchomotor tone and has therefore been described as an im-
portant mechanism in the pathophysiology of asthma (Boushey et al, 
1980). 
The cholinergic innervation of the lung appears mainly to be of 
importance in the larger airways, because stimulation of the vagal 
nerve leads to constriction of these larger airways but has little ef-
fect on smaller airways (Richardson, 1979). This appears to correlate 
with results of clinical studies showing that administration of para-
sympathicolytic agents such as atropine or ipratroprlumbromide mainly 
causes dilatation of larger airways (Ashutosh et al, 1980; Minette et 
al, 1985). Moreover, direct receptor binding studies and autoradiogra-
phy of mammalian lung have shown a high density of muscarinic recep-
tors In smooth muscles of larger airways, while the receptor amount 
decreases when airways become smaller (Barnes et al, 1983a). 
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Woolcock et al (1969b), on the contrary, stated that In dogs vagal 
tone Is present both In large and small airways, but Is masked In the 
latter by adrenergic mechanisms· 
It has been suggested that the parasympathetic ganglia and/or postgan­
glionic fibres In the bronchial wall possess sympathetic nerve endings 
by which cholinergic neurotransmission can be modulated (Nadel, 1980; 
Gross and Skorodln, 1984; Barnes et al, 1984). Sympathetic neural ac­
tivity and circulating adrenaline from the adrenal medulla or other 
3-adrenoceptor agonists could in this way influence cholinergic neu­
rotransmission. The great effectiveness of the ^-adrenoceptor agonists 
in asthma has, among other effects, been ascribed to such a modulating 
effect on the (hyper)activity of the cholinergic system (Vermeire and 
Vanhoutte, 1979; Barnes et al, 1984). The existence of adrenergic re­
ceptors or sympathetic nerve endings on postganglionic cholinergic 
neurons, however, is still uncertain (Nadel, 1980). 
2.3. ТНК NONADRENERGIC, NONCHOLINERGIC SYSTEM 
In 1976 Richardson and Beland described the existence of a third nerv­
ous system in the lung, which became known as the nonadrenergic, non-
cholinergic (NANC) system or nonadrenergic inhibitory system. While 
the cholinergic system is the excitatory nervous system of the lung, 
NANC nerves mediate relaxation of airway smooth muscles. Evidence of 
this inhibitory effect has been obtained from in-vitro experiments of 
animal and human airway smooth muscles (Richardson and Beland, 1976; 
Richardson, 1981; Taylor et al, 1984). Electrical field stimulation of 
airway smooth muscle with sufficient intrinsic tone resulted in a bi-
phasic response: contraction was followed by relaxation. The contrac­
tion could be abolished by atropine, while the relaxation remained. 
The relaxant response persisted in the presence of a ß-adrenoceptor 
antagonist, indicating its nonadrenergic character. Its neural nature 
has been deduced from the fact that the inhibitory effect can to some 
extent be blocked by neurotoxins such as tetrodotoxin. The nerves of 
this NANC system are supposed to run along the vagal nerves (Fig. 1). 
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The physiological or pathophysiological role of this system, however, 
is still unresolved and the neurotransmitter is yet to be identified. 
Vasoactive intestinal peptide (VIP) appears to be the most probable 
candidate (Barnes, 1984a). 
A defect in the NANC system may contribute to increased bronchial 
hyperreactivity in asthma but this hypothesis is still unproven 
(Richardson, 1981; Barnes, 1984a). 
2.4. THE ADRENERGIC SYSTEM 
2.4.1. The adrenergic innervation of the lung 
In contrast to the dense cholinergic nerve supply, the adrenergic in-
nervation of the lung is sparse and there is considerable variation in 
the density of this adrenergic innervation between different species 
(Nadel, 1980). Richardson and Béland (1976) and Davis et al (1982) 
were unable to demonstrate any adrenergic innervation in human lung 
preparations. More recently, however, Partanen et al (1982) using a 
special histochemical method, demonstrated a small number of adrener-
gic nerves in human bronchial smooth muscle from lobar bronchi to 
terminal bronchioli. A larger number of adrenergic nerves was present 
in the bronchial vessels and submucosal glands. Results of a study 
by Zaagsma et al (1983), however, pointed to the absence of adrenergic 
innervation of human bronchial smooth muscle. 
Electrical stimulation of the thoracic adrenergic nerves induces 
bronchodilatation in animals; this effect can be blocked by 0-adreno-
ceptor antagonists (Cabezas et al, 1971; Nadel, 1980). This adrenergic 
bronchodilator effect, however, occurs only in the presence of vagal 
bronchomotor tone, for it disappears when the vagal nerves are cut 
(Cabezas et al, 1971). Moreover, complete inhibition of vagal induced 
bronchoconstriction could not be achieved by adrenergic nerve stimula-
tion, Indicating predominance of the vagal constrictor pathways to 
the airways (Cabezas et al, 1971). Isolated human airways, however, 
did not show such an adrenergic inhibitory response (Davis et al, 
1982; Barnes, 1984b). Nevertheless, it has been suggested that 
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adrenergic nerves may modulate neurotransmission in the cholinergic 
ganglia located in the human airway wall (Barnes, 1984b; Fig. 1). Cir-
culating catecholamines and 0-adrenoceptor agonists could also inter-
act with p-adrenoceptors on these ganglia and in this way attenuate 
the cholinergic, excitatory activity. 
2.4.2. The adrenoceptors in the lung 
2.4.2.1. Introduction 
While adrenergic innervation is sparse or absent, there is a high den-
sity of adrenergic receptors ('adrenoceptors) in the lung and airways 
(Barnes et al, 1980 and 1982). Receptors can be defined as macromole-
cular structures on or in cells which serve as recognition sites for 
neurotransmitters, hormones or drugs. Receptor binding is followed by 
intracellular metabolic events which ultimately result in characteris-
tic physiological or pharmacological effects (Ariens and Simonis, 
1976; Lefkowitz et al, 1984). The magnitude of these effects depends 
on the affinity and the intrinsic activity of the agent that interacts 
with the receptor (Ariëns and Simonis, 1976). In this respect, drugs 
can be regarded as full agonists, partial agonists or full antago-
nists. A full agonist has affinity to the receptor and a high intrin-
sic activity, resulting in a maximal response after coupling to the 
receptor. A full antagonist has affinity to the receptor but lacks in-
trinsic activity and can prevent the action of an agonist by competi-
tion for the receptor site. A partial agonist has affinity to the re-
ceptor with a low intrinsic activity, which means that only part of 
the effect of a full agonist can be reached. A partial agonist can 
also behave as partial antagonist by displacing a full agonist from 
the receptor, resulting in a decrease of the response of the full ago-
nist to the level of the maximal response of the partial agonist (Ari-
ëns and Simonis, 1976; Ariëns, 1983). 
In 1948 Ahlquist proposed the existence of two types of adrenergic 
receptors: α-adrenoceptors and θ-adrenoceptors. Lands and coworkers 
in 1967 introduced a subclassification of the ß-adrenoceptors in two 
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subtypes: the 3}- and the ^adrenoceptor. These authors postulated an 
absolute organ separation between the 0^- and the ß2-adrenoceptors. 
Several years later, however, it became clear that 0^- and ^ a d r e -
noceptors can coexist In the same tissue or organ and mediate the 
same physiological response (Carlsson et al, 1972). The relative dis-
tribution of Βχ- and 32~adrenoceptors varies from organ to organ, 
within one organ system in different species (Carlsson et al, 1972; 
Lulich et al, 1976; Minneraan et al, 1979; Rugg et al, 1978), and with­
in one organ system In the same species (Zaagsma et al, 1983). Ariëns 
and Simonis (1976) proposed a differentiation of the 3-adrenoceptors 
in receptors for the neurotransmitter noradrenaline, hence called Зт-
adrenergic receptors, and receptors for the hormone adrenaline, Bj¡-
adrenergic receptors. This distinction of 3χ- and 3jj-adrenoceptors pa­
rallels the distinction of Βχ- and Ö2~adrenoceptors. 
For the βχ-adrenoceptor the relative potencies of agonists are: 
isoprenaline > adrenaline · noradrenaline. For the 32~a<lrenoceptor the 
relative potencies can be written as: isoprenaline » adrenaline »> 
noradrenaline (Minneman et al, 1979; Lefkowitz et al, 1984). For the 
α-adrenoceptors, too, a functional differentiation in οχ- and (^-sub­
types has been made (Berthelsen and Pettinger, 1977). 
2.4.2.2. The α-adrenoceptor system in the lung 
Although hyperresponslveness of the α-adrenergic system in asthma has 
been suggested (Henderson et al, 1979; Nadel and Barnes, 1984), it is 
still controversial whether the α-adrenoceptors play an important role 
in the control of bronchomotor tone (Barnes, 1981a). Alpha-adrenocep-
tor agonists are able to induce bronchoconstriction in patients with 
obstructive lung disease but not in normal subjects. However, this 
only occurred when concomitantly a 3-adrenoceptor antagonist with or 
without atropine was administered (Simonsson et al, 1972; Patel and 
Kerr, 1973). Recently, Goldie et al (1984) observed only weak a-adre-
noceptor-mediated contractions of human isolated bronchi in 3 of 9 
preparations tested. They concluded that α-adrenoceptors have no func­
tional significance in isolated normal human bronchi. Bronchodilata-
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tlon caused by o-adrenoceptor antagonists In asthmatics has been men­
tioned, but this effect could also have been the result of other phar­
macological actions of these drugs (Barnes, 1981a). 
In a study by Shiner and Molho (1983), for Instance, the a-anta-
gonlst phentolamlne induced bronchodilatation in some asthmatics, in 
other patients no reaction at all, and in 2 patients even bronchocon­
strlctlon. The aj-adrenoceptor antagonist prazosin did not cause a 
bronchodilatation in asthmatic patients at rest (Barnes et al, 1981a) 
but partially prevented the post-exercise bronchoconstrlctlon in chil­
dren with exercise-induced asthma (Barnes et al, 1981b). These authors 
suggested that this effect of prazosin may be due to blockade of a-
adrenoceptors on mast cells, resulting in diminished release of bron-
choconstrictive mediators by exercise. Otherwise, it might be that 
prazosin antagonizes o-adrenoceptor-mediated bronchoconstriction by an 
increase in noradrenaline during exercise. Recently, Jenkins et al 
(1985) demonstrated that inhaled prazosin partially protected sub­
jects with bronchial hyperreactivity against histamine-induced bron­
choconstrlctlon. 
Nevertheless, it seems that, at least for the time being, α-adreno­
ceptor antagonists are of minor importance in the treatment of pa­
tients with CNSLD. 
2.4.2.3. The 0-adrenoceptor system In the lung 
Both βγ- and B2-adrenoceptor8 are located on the cell membrane and 
stimulate the same biochemical effector, i.e. the adenylate cyclase 
system, which generates З'^'-сусИс AMP (cAMP) (Lefkowitz et al, 
1984). cAMP can be regarded as a second messenger, generating cellular 
processes which lead to the 0-adrenoceptor mediated effects. After 
coupling of the agonist or hormone (H) to the receptor (R) a receptor-
hormone complex (HR) is formed which consecutively binds a guanine 
nucleotide regulatory protein (N). This results in conversion of the 
receptor from a state of low affinity for the hormone to a high affi-
nitity state which binds the hormone tightly (HRN complex). Guanoslne 
triphosphate (GTP) binds to the HRN complex and activates N. This re-
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suits In the formation of a N-CTP complex which activates adenylate 
cyclase, which in turn catalyses the conversion of adenosine triphos-
phate in cAMP (Lefkowitz et al, 1984). 
The density and the characteristics of receptors can be demonstra-
ted by means of radioligand binding studies and autoradiography. 
In radioligand binding studies, radioactively labelled adrenocep-
tor antagonists such as •'H-dihydro-alprenolol or ^¿^I-iodocyanopindo-
lol, bind to adrenoceptors on the cell surface. 0-Adrenoceptor affini-
ty and density can be determined by this method. Moreover, differen-
tiation between 0^- and 02-adrenoceptor subtypes is possible by using 
selective agonists and antagonists (Fig. 2) (Rugg et al, 1978; Barnett 
et al, 1978; Barnes et al, 1980). 
Fractienol sptcifie(125i)-(-)-CYP binding 
-8 -7 -β - 5 -4 
log ICI 118,551 ( m o l / l ) 
Figure 2. 
Competition of the 02~adrenoceptor selective antagonist ICI 118, 551 
for (l-25;[)_(_)_cy
an0pin(j0ioi (CYP) binding sites on membrane homoge-
nates of normal human lobar bronchus tissue. 
ICI 118,551 displaces (125I)-(-)-CYP from the 0-adrenoceptors in the 
tissue homogenates in a dose-dependent manner. From the shape of the 
curve it can be concluded that both 02" and 0^-adrenoceptors are pre­
sent in human lobar bronchus tissue. The ratio of 02:0i-adrenoceptors 
is approximately 4:1. 
(This figure was kindly provided by Ch. van Koppen, Dept. of Pharma­
cology, University of Nymegen.) 
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A disadvantage of the radioligand binding technique Is that tis-
sue homogenates are generally used, which makes It difficult to assess 
receptor density on different cell types (Barnes, 1984b). More recent-
ly, however, autoradiography has been introduced as a semiquantitative 
method to determine the density of receptors on different cell types 
(Scott Young and Kuhar, 1979; Barnes et al, 1982/1983a). The principle 
of this method is that slide-mounted sections of a tissue are incubat-
ed with a radioligand. Next, coverslips coated with a photographic 
emulsion, are fixed on these slides and after a certain exposure time 
the receptors bound by the radioligand can be localized in the tis-
sue sections (Scott Young and Kuhar, 1979). Both techniques have been 
used to localize 8-adrenoceptors in mammalian lung and to differen-
tiate between the 3i- and the e2-subtypes (Rugg et al, 1978; Barnett 
et al, 1978; Barnes et al, 1980; Barnes et al, 1982/1983a). 
With regard to the human lung it appears that the ratio of &2~ t o 
ß^-adrenoceptors is approximately 3:1 (Carstairs et al, 1985) or 
4:1 (Fig. 2); these ratios have also been demonstrated in other 
species (Rugg et al, 1978; Barnett et al, 1978; Barnes et al, 1983b). 
Carstairs et al (1985) demonstrated by means of autoradiography that 
S-adrenoceptors occur not only on human airway and vascular smooth 
muscles but in even higher densities on airway epithelium, submucosal 
glands and alveolar walls. They demonstrated a homogeneous population 
of 62~adrenoceptors on airway smooth muscles of large and small air-
ways, on airway epithelium, and on vascular smooth muscles. This was 
confirmed in functional studies for human airway smooth muscles by 
others (Zaagsma et al, 1983). Bronchial submucosal glands and alveolar 
walls appeared to contain both ß^- and 02 - ad r e n o c eP t o r s· 
The e-adrenoceptor density in the airway smooth muscle increases 
from large to small airways (Carstairs et al, 1985) as has also been 
shown for the ferret (Barnes et al, 1983a). 
Adrenoceptor density is regulated by a variety of physiological and 
pathophysiological processes (Lefkowitz et al, 1984; Venter and Fra-
ser, 1985). Adrenergic agonists and antagonists and hormones such as 
glucocorticoids and thyroid hormone can also influence adrenoceptor 
density. The beneficial effects of glucocorticoids during an asthmatic 
attack, for example, have been attributed to an increase in ß-adreno-
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ceptor density (Venter and Fraser, 1985). 
These authors also demonstrated autoantibodies against 3-adrenocep-
tors (Fraser et al, 1981) and they suggested that in some asthmatics 
autoantibodies to S 2 - a d r e n o c e P t o r s т аУ mediate a state of "0-adrener-
gic hyporesponsiveness". Since these autoantibodies were also demon­
strated in plasma of apparently normal subjects, it is still uncertain 
whether they are important in asthma. 
Szentivanyi (1968) postulated impaired 0-adrenoceptor function as a 
fundamental factor in the aetiology of asthma. A reduced number and 
function of 0-adrenoceptors on circulating blood cells of asthmatics 
has indeed been demonstrated (Brooks et al, 1979; Tashkin et al, 
1982). Nevertheless, the hypothesis of Szentivanyi has been questioned 
because the decrease in 3-adrenoceptor density in these patients 
was at least partly due to chronic 0-adrenoceptor agonist treatment, 
which results in desensitization or down-regulation of the adrenocep­
tor density of the cell (Galant et al, 1980; Djurup, 1981). Desensi­
tization involves a reversible loss of receptor responsiveness which 
can be the consequence of overstimulation by agonistic drugs (Dju­
rup, 1981; Lefkowitz et al, 1984). 
Several clinical studies of the effects of chronic treatment with 
bronchodllators on the response to a 0-adrenoceptor agonist in asthma­
tic patients have not yielded arguments for an attenuation of this 
response (Larsson et al, 1977; Harvey and Tattersfield, 1982; Tatters-
field, 1985). The process of desensitization therefore appears not to 
be of clinical relevance in the treatment of patients with CNSLD with 
0-adrenoceptor agonists. 
Additional information on the function of ^-adrenoceptors in the lung 
and airways can be obtained by functional in-vitro studies, e.g. by 
contraction and relaxation of airway smooth muscles. Some results of 
such studies of human bronchial tissue are now available (Zaagsma et 
al, 1983; Goldie et al, 1984), but further results are to be awaited. 
The function of the 0-adrenergic system in the lung can also be 
studied by investigating the effects of 0-adrenoceptor agonists and 
antagonists on various pulmonary functions. Since 0-adrenoceptors re-
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guíate several processes In the lung and airways, 0-adrenerglc drugs 
can Influence these biological processes. Some of these effects of 0-
adrenoceptor agonists and antagonists are listed In the table (next 
page). Most of the Information on ß-adrenoceptor functions, however, 
Is obtained from animal studies, mainly because of technical problems. 
Several effects of 0-adrenergic agonists and antagonists are still to 
be clarified. 
As mentioned before, 0-adrenoceptor antagonists can cause broncho-
constriction in patients with asthma. Since atropine can reduce this 
increase in airway resistance (MacDonald et al, 1967; Grieco et al, 
1971), it appears that unopposed cholinergic activity is the main 
cause of 0-blocker-induced bronchoconstriction. From results of animal 
experiments it has been suggested that ß-blocklng agents also cause 
bronchoconstriction by inhibition of adrenergic modulation of choli-
nergic tone (Cabezas et al, 1971). If this mechanism exists in man as 
well, it may be possible that both 0-adrenoceptor agonists and antago-
nists, apart from a direct effect on airway smooth muscles, also have 
an effect on cholinergic ganglia or postganglionic fibres in the air-
way wall (Fig. 1). 
McLagan and Ney (1979) demonstrated in guinea pigs and rats a 50% 
reduction in propranolol-induced bronchoconstriction after intravenous 
administration of dlsodlum cromoglycate. Koëter et al (1982) found in 
asthmatic patients a protective effect of cromoglycate against bron-
choconstriction induced by inhalation of propranolol. Since it is 
assumed that cromoglycate is an inhibitor of mediator release from 
lung mast cells, it could be that 0-adrenoceptor antagonists also 
cause bronchoconstriction by release of mediators from lung mast 
cells. 
0-Adrenoceptor agonists mainly cause bronchodilatation by a direct 
effect on the 02-adrenoceptors in the airway smooth muscles. Like the 
bronchoconstrictor effect of 0-adrenoceptor antagonists the bronchodi-
lator effect of 0-adrenoceptor agonists can be demonstrated easily in 
man by measuring lung function parameters, as described in Chapter 3· 
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TABLE Effects of 0-adrenoceptor agonists and antagonists on various 
structures and cell types of the lung 
Structure/ 
cell type 
adrenoceptor g-agonlst 
subtype 
g-antagonlst 
Airway smooth muscle 02 relaxation contraction 
Mast cell 32 
Vascular smooth muscle 02 
Inhibition degranulatlon 
mediator release 
relaxation contraction 
Parasympathetic 
ganglia/nerves 
Submucosal gland 
Airway epithelium 
Alveoli 
βι* 
02* 
02**81 
02 
02»»01 
transmission 
inhibition* 
increase mucus 
secretion 
increase fluld+ 
ion transport 
increase in 
mucociliary 
clearance 
increase sur­
factant release; 
increase in lung 
fluid absorption 
* 
transmission 
enhancement* 
no influence 
* 
decrease 
* 
decrease in 
gas exchange 
* still to be clarified. 
Modified after Barnes, 1984b. (For other references see also Gatto et 
al, 1984). 
28 
LITERATURE 
Ahlqulst RP. A study of the adrenotroplc receptors. Am J Physiol 153: 
586-600, 1948. 
Arlens EJ, Simonis AM. Receptors and receptor mechanisms. In: Beta-
adrenoceptor blocking agents. Saxena PR, Forsyth RP, eds. North-
Holland Pubi Comp, Amsterdam, 1976· 
Ariens EJ. Intrinsic activity: partial agonists and partial antago-
nists. J Cardiovasc Pharmacol 5 (Suppl 1): S8-S15, 1983. 
Ashutosh K, Mead G, Dickey JC, Berman P, Kupplnger M. Density depen-
dence of expiratory flow and bronchodilator response in asthma. Chest 
77: 65-75, 1980. 
Barnes PJ, Karllner JS, Dollery CT. Human lung adrenoreceptors studied 
by radioligand binding. Clin Sci 58: 457-461, 1980. 
Barnes PJ, Ind PhW, Dollery CT. Inhaled prazosin in asthma. Thorax 36: 
378-381, 1981a. 
Barnes PJ, Wilson NM, Vickers H. Prazosin, an alpha^-adrenoceptor 
antagonist, partially inhibits exercise-Induced asthma. J Allergy Clin 
Immunol 68: 411-415, 1981b. 
Barnes PJ, Basbaum CB, Nadel JA, Roberts JM. Localization of ß-adreno-
receptors in mammalian lung by light microscopic autoradiography. 
Nature 299: 444-447, 1982. 
Barnes PJ, Basbaum CB, Nadel JA. Autoradiographic localization of 
autonomic receptors In airway smooth muscle. Marked differences 
between large and small airways. Am Rev Resp Dis 127: 758-762, 1983a. 
Barnes PJ, Nadel JA, Skoogh B-Ε, Roberts JM. Characterization of beta-
adrenoceptor subtypes in canine airway smooth muscle by radioligand 
binding and physiological responses. J Pharmacol Exp Ther 225: 1539-
1545, 1983b. 
Barnes PJ. The third nervous system In the lung: physiology and clini­
cal perspectives. Thorax 39: 561-567, 1984a. 
Barnes PJ. Beta-adrenoceptors in lung tissue. In: Morley J, ed. Beta-
adrenoceptors In asthma. London, Academic Press: 67-95, 1984b. 
Barnes PJ, Ind PhW, Dollery CT. 0-Adrenoceptors in asthma and their 
response to agonists. In: Asthma. Physiology, immunopharmacology, and 
treatment. Kay AB, Austen KF, Lichtenstein LM, eds. Academic Press, 
London, 339-358, 1984. 
29 
Barnett DB, Rugg EL, Nahorski SR. Direct evidence of two types of 0 
adrenoceptor binding site in lung tissue. Nature 273: 166-168, 1978. 
Berthelsen S, Pettinger WA. A functional basis for classification of 
o-adrenergic receptors. Life Sci 21: 595-606, 1977. 
Boushey HA, Holtzman MJ, Sheller JR, Nadel JA. Bronchial hyperreacti-
vity. Am Rev Resp Dis 121: 389-413, 1980. 
Brooks SM, McGowan K, Bernstein IL, Altenau P, Peagler J. Relationship 
between numbers of beta adrenergic receptors in lymphocytes and 
disease severity in asthma. J All Clin Immunol 63: 401-406, 1979. 
Cabezas GA, Graf PD, Nadel JA. Sympathetic versus parasympathetic ner-
vous regulation of airways in doge. J Appi Physiol 31: 651-655, 1971. 
Carlsson E. Ablad B, Brändström A, Carlsson B. Differentiated blockade 
of the chronotropic effects of various adrenergic stimuli in the cat 
heart. Life Sci 11: 953-958, 1972. 
Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of 
beta-adrenoceptor subtypes in human lung. Am Rev Resp Dis 132: 541-
547, 1985. 
Davis C, Kannan MS, Jones TR, Daniel ЕЕ. Control of human airway 
smooth muscle: in-vitro studies. J Appi Physiol 53: 1080-1087, 1982. 
Djurup L. Adrenoceptors: molecular nature and role in atopic diseases. 
Allergy 36: 298-307, 1981. 
El-Bermani Al-W, Grant M. Acetylcholinesterase-posltive nerves of the 
rhesus monkey bronchial tree. Thorax 30: 162-170, 1975. 
Fraser CM, Venter JC, Kaliner M. Autonomic abnormalities and autoanti­
bodies to 8-adrenergic receptors. N Engl J Med 305: 1165-1170, 1981. 
Galant SP, Duriseti L, Underwood S, Allred S, Insel PA. Beta adrener­
gic receptors of polymorphonuclear particulates in bronchial asthma. 
J Clin Invest 65: 577-585, 1980. 
Gatto С, Johnson MG, Seybold V, Kulik ThJ, Lock JE, Johnson DE: 
Distribution and quantitative developmental changes in guinea pig 
pulmonary 0-receptors. J Appi Physiol: Respirât Environ Exercise 
Physiol 57: 1901-1907, 1984. 
Goldie RG, Paterson JW, Spina D, Wale JL. Classification of $-adreno-
ceptors in human isolated bronchus· Br J Pharmacol 81: 611-615, 1984. 
Greefhorst АРМ. Beta^-selective adrenoceptor antagonists in chronic 
non-specific lung disease. Thesis, Nymegen, 1983. 
30 
Grleco ΜΗ, Pierson RN. Mechanism of bronchoconstriction due to beta-
adrenergic blockade. Studies with practolol, propranolol, and atro­
pine. J All Clin Immunol 48: 143-152, 1971. 
Gross HJ, Skorodin MS. Role of the parasympathetic system in airway 
obstruction due to emphysema. N Engl J Med 311: 421-425, 1984. 
Harvey JE, Tatterefield AE. Airway response to salbutamol: effect of 
regular salbutamol inhalations in normal, atopic, and asthmatic sub­
jects. Thorax 37: 280-287, 1982. 
Henderson WR, Shelhamer JH, Reingold DB, Smith LJ, Evans R, Kaliner M. 
Alpha-adrenergic hyper-responsiveness in asthma· N Engl J Med 300: 
642-647, 1979. 
Jenkins Ch, Breslin ABX, Marlin GE. The role of alpha and beta adre­
nergic in airway hyperresponsiveness to histamine. J Allergy Clin 
Immunol 75: 364-372, 1985. 
Koëter GH, Meurs H, de Monchy JGR, Vries К de. Protective effect of 
disodium cromoglycate on propranolol challenge. Allergy 37: 587-590, 
1982. 
Koppen CJ van. Rodrigues de Miranda JF, Beld AJ, Hermanussen MW, 
Lammers JWJ, Ginneken CAM van. Characterization of the muscarinic 
receptor in human tracheal smooth muscle· Naunyn-Schmiedeberg's Arch 
Pharmacol 331: 247-252, 1985. 
Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG. Differentia­
tion of receptor systems activated by sympathomimetic amines. Nature 
214: 597-598, 1967. 
Larsson S, Svedmyr N, Thlringer G. Lack of bronchial beta adrenoceptor 
resistance in asthmatics during long-term treatment with terbutaline. 
J All Clin Immunol 59: 93-100, 1977. 
Lefkowitz RJ, Caron MG, Stiles GL. Mechanisms of membrane-receptor 
regulation. Biochemical, physiological, and clinical insights derived 
from studies of the adrenergic receptors. N Engl J Med 310: 1570-1579, 
1984. 
Lulich KM, Mitchell HW, Sparrow MP. The cat lung strip as an in vitro 
preparation of peripheral airways: a comparison of ß-adrenoceptor 
agonists, autocoids, and anaphylactic challenge on the lung strip and 
trachea. Br J Pharmacol 58: 71-79, 1976. 
MacDonald AG, Ingram CG, McNeill RS. The effect of propranolol on air-
way resistance. Br J Anaesth 39: 919-926, 1967. 
MacLagan J, Ney UM. Inhibition of propranolol-induced bronchospasm by 
sodium cromoglycate. Br J Pharmacol 67: 488P, 1979. 
31 
McNeill RS. Effect of a 3-adrenergic-blocking agent, propranolol, on 
asthmatics. Lancet, II: 1101-1102, 1964. 
Minneman KP, Hegstrand LR, Molinoff PB. The pharmacological specifi­
city of beta-1 and beta-2 adrenergic receptors in rat heart and lung 
in vitro. Mol Pharmacol 16: 21-33, 1979. 
Minette Ρ, Dubois P. Delwiche .TP. Validity of air-helium Dv
m
ax 
measurements in trials of bronchodilators. Clin Resp Physiol 21: 
357-362, 1985. 
Nadel JA. Physiology and pharmacology of the human airways. Marcel 
Dekker, New York, 1980. 
Nadel JA. Adoration of the vagi? N Engl J Med 311: 463-464, 1984. 
Nadel JA, Barnes PJ. Autonomic regulation of the airways. Ann Rev Med 
35: 451-467, 1984. 
Partanen M, Laitinen A, Hervonen A, Toivanen M, Laitinen LA. Catecho­
lamine- and acetylcholinesterase-containing nerves in human lower 
respiratory tract. Histochemistry 76: 175-188, 1982. 
Patel KR, Kerr JW. The airways response to phenylephrine after 
blockade of alpha and beta receptors In extrinsic bronchial asthma. 
Clin Allergy 3: 439-448, 1973. 
Richardson J, Beland J. Nonadrenergic inhibitory nervous system in 
human airways. J Appi Physiol 41: 764-771, 1976. 
Richardson JB. Nerve supply to the lungs. Am Rev Resp Dis 119: 
785-802, 1979. 
Richardson JB. Nonadrenergic inhibitory Innervation of the lung. 
Lung 159: 315-322, 1981. 
Rugg EL, Barnett DB, Nahorski SR. Coexistence of beta} and beta2 
adrenoceptors in mammalian lung: evidence from direct binding studies. 
Mol Pharmacol 14: 996-1005, 1978. 
Scott Young W, Kuhar MJ. A new method for receptor autoradiography: 
[3H]opioid receptors in rat brain. Brain Res 179: 255-270, 1979. 
Shiner RJ, Molho Ml. Comparison between an o-adrenergic antagonist and 
a 02~adrenergic agonist in bronchial asthma. Chest 83: 602-606, 
1983. 
Simonsson BG, Svedmyr N, Skoogh B-Ε, Andersson R, Bergh NP. In vivo 
and in vitro studies on alpha-receptors in human airways. Potentiation 
with bacterial endotoxin. Scand J Resp Dis 53: 227-236, 1972. 
32 
Szentivanyi A. The beta-adrenergic theory of atopic abnormality in 
bronchial asthma. J Allergy 42: 203-232, 1968. 
Tashkin DP, Connolly ME, Deutsch RJ, Kit Hui К, Littner M, Scarpace 
Ph, Abrass I. Subsensitization of beta-adrenoceptors in airways and 
lymphocytes of healthy and asthmatic subjects. Am Rev Resp Dis 125: 
185-193, 1982. 
Tattersfleld AE, Leaver DG, Pride NB. Effects of 0-adrenergic blockade 
and stimulation on normal human airways. J Appi Physiol 35: 613-619, 
1973. 
Tattersfleld AE. Tolerance to beta-agonists. Clin Resp Physiol 21: 
1S-5S, 1985. 
Taylor SM, Paré PD, Schellenberg RR. Cholinergic and nonadrenergic 
mechanisms in human and guinea pig airways· J Appi Physiol: Respirât 
Environ Exercise Physiol 56: 958-965, 1984. 
Venter JC, Fraser CM. Beta-adrenergic receptor structure, synthesis, 
antibodies and human disease. Clin Resp Physiol 21: 13S-18S, 1985. 
Vermeire PA, Vanhoutte PM. Inhibitory effects of catecholamines in 
isolated canine bronchial smooth muscle. J Appi Physiol 46: 787-791, 
1979. 
Widdicombe JG, Kent DC, Nadel JA. Mechanisms of bronchoconstrictlon 
during inhalation of dust. J Appi Physiol 17: 613-616, 1962. 
Woods KL, Linton SP, Kendall MJ, Faragher EB, Grieve RJ. Exercise 
responses of healthy subjects in the evaluation of cardioselectivity 
of e-blockers. Eur J Clin Pharmacol 15: 229-233, 1979. 
Woolcock AJ, Macklem PT, Hogg JC, Wilson HJ, Nadel JA, Frank NR, 
Brain J. Effect of vagal stimulation on central and peripheral airways 
in dogs. J Appi Physiol 26: 806-813, 1969a. 
Woolcock AJ, Macklem PT, Hogg JC, Wilson NJ. Influence of autonomic 
nervous system on airway resistance and elastic recoil- J Appi Physiol 
26: 814-818, 1969b. 
Zaagsma J, Heijden PJCM van der, Schaar MWG van der. Bank CMC. 
Comparison of functional ß-adrenoceptor heterogeneity in central and 
peripheral airway smooth muscle of guinea pig and man. J Receptor Res 
3: 89-106, 1983. 
33 

CHAPTER 3 
BETA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS 
AND THEIR EFFECTS ON DYNAMIC LUNG FUNCTION PARAMETERS 
IN PATIENTS WITH CNSLD 
3.1. INTRODUCTION 
Soon after the introduction of nonselective @-adrenoceptor antagonists 
it became clear, that these drugs can induce severe bronchoepasm in 
asthmatic patients (McNeill, 1964). ß-adrenoceptor agonists on the 
other hand can induce bronchodilatation as has been described in Chap-
ter 2. These changes in airway calibre can be measured as a change in 
a) airway resistance, b) airflow, c) expired volume. 
A schematic representation of the airway system is shown in Figure 
1. 
extrothoracic airways 
larger intrathoracic / 
airways / \ 
(diameter > 2 mm) / \ 
smaller airways / \ 
(diameter< 2π\π\)/ ^ 
Figure 1 Schematic representation of the airway system. The total 
cross sectional area of the extrathoracic airways and trachea 
is 2.5 cm^, of the larger intrathoracic airways approximately 
40 cm^ and of all alveolar ducts and sacs about 70 m^. 
The total cross sectional diameter of the airways increases from the 
mouth to the alveoli. The total flow resistance is therefore high in 
the trachea and extrathoracic airways, somewhat lower in the larger 
intrathoracic airways and resistance decreases rapidly towards the 
periphery of the lung. Because airflow and total airways diameter are 
inversely related to each other, airflow is high in extrathoracic and 
larger intrathoracic airways and low in smaller airways. 
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Several methods for assessment of the effects of 0-adrenoceptor a-
gonlsts and antagonists on airway resistance and airflow will be dis-
cussed in this Chapter, as is summarized In the Table· 
Table Summary of lung function parameters, assessment procedures 
and their main sensitivities for large and/or small airways 
function. 
Lung function 
parameters 
Assessment 
procedure 
Large airways and/or 
small airways function 
Total airway 
resistance 
Peak expiratory 
flow rate 
Forced expiratory 
volume in 1 sec 
Closing volume 
Frequency depen-
dence of lung 
compliance 
Flow-volume 
curve 
body Plethysmograph 
forced oscillation 
technique 
interrupter technique 
peak flow meter 
pneumotachograph 
spirometer 
pneumotachograph 
single breath 
N2-washout technique 
esophageal balloon 
+ pneumotachograph 
pneumotachograph 
mainly large 
airways function 
large airways 
function 
mainly large 
airways function 
small airways 
function 
small airways 
function 
large and small 
airways function 
For explanation of lung function parameters and assessment procedures: 
see text. 
First, measurement of total airway resistance, peak expiratory flow 
rate and the forced expiratory volume in one second are described, as 
these parameters are thought to reflect mostly large airways function. 
From studies of "healthy" smokers without signs of chronic non-
specific lung disease (CNSLD) it became clear that with conventional 
lung function tests changes in airway calibre could not be assessed; 
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however, with more sophisticated methods changes in the calibre of 
small, peripheral airways could be demonstrated (Buist and Ross, 1973; 
Dosman et al, 1975; Martin et al, 1975). Since the introduction by 
Mead et al (1967) of the "equal pressure point" concept, it appears 
that the airway system functionally can be divided into a more cen-
tral part on the one hand, and a more peripheral part on the other 
hand. Via pathological studies it became clear, that there is also 
a morphological substrate for the changes in small airways function 
and the concept of "small airways disease" was developed (Hogg et al, 
1968; Cosió et al, 1977; Petty et al, 1980). These peripheral air-
ways are anatomically defined as the airways with a diameter of 2 to 3 
mm or less. Aerodynamically small airways are those in which airflow 
is laminar in contrast to the more turbulent flow in the larger air-
ways during forced expiratory manoeuvres (Ingram and McFadden, 1979). 
Several studies dealing with small airways dysfunction have been di-
rected to discover early changes in airflow, e.g. in smokers and indu-
strial workers (Martin et al, 1975; Brown et al, 1977, Nemery et al, 
1981; Cotton et al, 1982). In the last decade there has also developed 
an increasing interest in performing these tests to discriminate be-
tween the effects on large and small airways function of bronchocon-
strictor and bronchodilator agents (Ingram et al, 1977; Brown et al, 
1977; Chan-Yeung et al, 1976; Ashutosh et al, 1980). 
Measurements of closing volume and frequency dependence of lung 
compliance are two tests which are used to discover changes in small 
airways function when other lung function tests are still normal. 
Finally, the flow-volume curve is discussed as a relatively simple 
lung function test, which is suited to measure simultaneously large 
and small airways function. 
3.2. ASSESSMENT OF LARGER AIRWAYS FUNCTION 
3.2.1. Measurement of total airway resistance 
The measurement of airway resistance (Raw) is usually performed with a 
body Plethysmograph (Dubois et al, 1956a). This method has the advan-
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tage that thoracic gas volume (TGV) can be measured at the same time. 
As airway resistance varies with lung volume, this resistance Is usu-
ally expressed as a conductance/volume ratio. Airway conductance (Gaw) 
Is the reciprocal of airway resistance and when TGV Is known specific 
airway conductance (sGaw) can be calculated: sGaw = Gaw 
TGV 
(Briscoe and Dubois, 1958; Tattersfield and Keeping, 1979). 
In contrast to the methods discussed below measurement of Raw is 
relatively easy to do, even for dyspnoeic patients and this procedure 
also excludes the contribution of dynamic compression of the airways 
as occurs during a forced expiration manoeuvre. Another advantage of 
this method is its great sensitivity to detect changes in airway cali-
bre. It does, however, not distinguish between the contribution of ex-
trathoracic and intrathoracic airways to total airway resistance, 
which is particularly disadvantageous in assessing airway responses of 
pharmacological agents (Ingram and McFadden, 1977). Also the reprodu-
cibility of measuring Raw with the body Plethysmograph is probably not 
very good: there is a high within-subject variability with mean values 
for the coefficient of variation between 10% and 20% with a large 
range which necessitates several measurements (5-10) (Pelzer and 
Thompson, 1966). 
Raw can also be determined with the forced oscillation technique 
as described by DuBois et al (1957b), which method might have a bet-
ter reproducibility (Tattersfield and Keeping, 1979). This technique 
has the advantage over the body Plethysmograph that the necessary e-
qulpment is much cheaper. However, forced oscillation has not been 
used frequently yet to assess airway responses to pharmacological 
agents. 
Recently, the Interrupter technique, as described in 1954 by Mead 
and Whlttenberger to measure total airway resistance has gained new 
interest (Jackson et al, 1974; Shaw et al, 1983). This method, how-
ever, seems to be less useful in bronchial challenge testing, since 
its validity in severely obstructed patients has been described con-
troversially (Eiser et al, 1983). 
Measurement of Raw is often used in the assessment of broncho-
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dilatation by 0-adrenoceptor agonists and bronchoconstriction by 0-
adrenoceptor antagonists in patients with CNSLD. Tattersfield and co-
workers (1979 and 1983) have also used the plethysmographical assess-
ment of Raw as a sensitive method to determine the Sj-adrenoceptor 
selectivity of different 3-adrenoceptor antagonists in healthy sub-
jects. For this purpose they compared the displacement of sGaw dose-
response curves with a 32~adrenoceptor agonist during different types 
of 3-blockers. The main objective for performing these test in normal 
subjects was to avoid side effects of ß-blockers in patients with 
CNSLD. Although this method seems to be suitable for assessing the @^-
adrenoceptor selectivity of ß-blockers, it does not give full Informa-
tion of the bronchoconstrictor effects of 0-blocking agents in pa-
tients with CNSLD, because ß-blockers do not cause bronchoconstriction 
in normal subjects (Kumana and Ruffin, 1978; Woods et al, 1979). 
3.2.2. Peak expiratory flow rate 
Soon after the introduction of the peak flow meter in 1959 by 
Wright and McKerrow measurement of peak expiratory flow rate (PEFR) 
became one of the most popular methods to assess airway responses to 
pharmacological agents. The great advantage of PEFR measurement is the 
simplicity for patient and investigator. It is also the only practical 
method at this moment to assess the lung function of the patient at 
home (Pride, 1979), which can be very helpful to detect a diurnal 
rhythm in the airway conductance of the asthmatic patient. This method 
can effectively be used to evaluate short-term and long-term effects 
of medication on pulmonary function of patients with CNSLD, both in 
hospitalized patients and in situations outside the hospital. PEFR-
measurement seems to be good reproducible. McCarthy et al (1975) mea-
sured a coefficient of variation (CV) for this parameter of 5 to 6% in 
normal subjects. Nlckerson et al (1980) measured for PEFR a CV of 5.8% 
in normals and of 6.6% in patients with cystic fibrosis. In one of our 
studies (Chapter 4) we found a within-subject CV of 5.8 + 3.5% (mean + 
SD) in asthmatic patients during a stable stage of their disease as 
assessed with the Wright peak flow meter (Fig. 2, left panel). 
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However, the value of PEFR can show false high readings due to dy­
namic compression of the airways. This phenomenon can be unmasked by 
taking flow-volume curves (see Paragraph 3.4). 
CV(%) spirometry 
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Figure 2 Coefficients of variation (CV) for intrasubject reproduci­
bility of lung function parameters in asthmatic patients 
during a stable phase of their disease. 
Left panel: mean CV (+SD) of parameters as measured with 
spirometry on 4 different days in 8 patients. 
Right panel: mean CV (+SD) of parameters as measured with 
MEFV curves on 3 different days in 11 patients when breath­
ing air and a helium-oxygen (НеОз) mixture. 
3.2.3. Forced expiratory volume In one second 
The forced expiratory volume in one second (FEV^) can be assessed by 
spirometry or can be derived from flow-volume curves (see Paragraph 
3.4). Like peak flow rate the measurement of FEV} is easy to perform. 
It is one of the most reproducible lung function parameters: within-
subject coefficients of variation vary from 2.5 to 5.3% (Nickerson et 
al, 1980). We found a CV for FEVi of 6.4 + 4.6% (mean+SD) as assessed 
by spirometry and of 6.2 + 6.1% when FEV]^ was derived from flow-volume 
curves (Fig. 2). The FEV^ appears to have a lower sensitivity in de-
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tectlng changes In airway calibre due to bronchoconstrictor agents 
than other lung function tests. It is, however, the most specific test 
for assessment of bronchoconstriction (Michoud et al, 1982). It has 
to be therefore one of the mainstays in the assessment of ventilatory 
effects of 0-adrenoceptor agonists and antagonists in man. 
The fact that g-adrenoceptor antagonists do not affect FEV^ in 
normal subjects should caution against drawing too many, if any, con-
clusions from studies of ventilatory effects of 0-blockade in normal 
men. Like PEFR, FEV^ is relatively insensitive to changes in the peri-
pheral airways. 
FEVi and PEFR are both assessed during a maximal expiratory manoeu-
vre after a preceding maximal inspiration. Particularly this deep in-
spiration can by itself have an effect on bronchomotor tone (Nadel and 
Tierney, 1961; Gayrard et al, 1975; Fish et al, 1977; Orehek. et al, 
1980), possibly induced by a vagal reflex mechanism or via a local 
mechanism in the airway smooth muscle (Zamel, 1984). In normal sub-
jects at rest the inspiratory manoeuvre has no effect, however, during 
pharmacologically induced bronchoconstriction it can cause in the same 
subjects without CNSLD a bronchodilatation (Fish et al, 1977). In 
asthmatic patients on the other hand the effects of deep inspiration 
are variable: at normal resting conditions it can cause an increase in 
airway resistance (Gayrard et al, 1975; Orehek et al, 1980), whereas 
after inhalation of bronchoconstrictor pharmacological agents the ef-
fect of the deep inspiratory manoeuvre is unpredictable, varying from 
bronchoconstriction to bronchodilatation (Fish et al, 1977). 
With regard to the effects of fi-blockade on lung function, there 
are at present few data available concerning the combined effects of 
systemically administered 3-adrenoceptor antagonists and the manoeuvre 
of deep inspiration on bronchomotor tone in patients with CNSLD. Gay-
rard et al (1975) found only in 4 out of 14 asthmatic patients a po-
tentiation of the bronchoconstrictor effect of intravenously adminis-
tered propranolol, as measured by an increase in specific airway re-
sistance, by the inspiratory manoeuvre. There was, however, no signi-
ficant mean increase in the effect of deep inspiration on airway re-
sistance after propranolol in comparison with the control group. 
Moreover, as stated by Orehek (1982), the use of maximal expiratory 
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manoeuvres for measurement of bronchoconstrictor effects of pharmaco­
logical agents is only misleading in those asthmatics in whom deep in­
spiration causes bronchodilatation, which may leave the FEV^ e.g. er­
roneous unchanged• 
3.3. ASSESSMENT OF SMALLER AIRWAYS FUMCTION 
3.3.1. Closing volume 
The single-breath nitrogen washout technique has gained a lot of 
interest for the detection of peripheral airways obstruction. Buist 
and Ross (1973) stated that it can be used to evaluate three aspects 
of lung function: uniformity of alveolar ventilation, residual volume 
and the lung volume at which dependent lung zones cease to ventilate 
(closing volume). The advantage of this test is, that it is relatively 
easy to perform: after a deep inspiration of 100% oxygen or a tracer 
gas to total lung capacity (TLC), a slow expiratory vital capacity 
(VC) follows during which the concentration of nitrogen or tracer gas 
is recorded versus expired volume (Fig 3) (next page). 
The slope of the alveolar plateau (Phase III) is determined and al­
so the increase in nitrogen concentration (percent) per liter (ΔΝ2/Ι)· 
The closing volume (CV) has been defined as the difference between re­
sidual volume (RV) and the transition between the alveolar plateau 
(Phase III) and the last steep part of the nitrogen washout curve 
(Phase IV). Closing volume is usually expressed as percentage of VC: 
CV/VC%. Closing capacity (CC) being the gas volume in the lung at the 
transition between Phases III and IV, is also used and expressed as 
percentage of TLC: CC/TLC%. (For a more detailed description of this 
test, see Sterk, 1981.) 
Several studies have demonstrated the usefulness of this test as a 
method to detect small airways dysfunction (Gelb and Zamel, 1973; 
Cochrane et al, 1974; McFadden et al, 1974; Nemery et al, 1981). Data 
concerning the correlation between pathological changes in small air­
ways and abnormalities in the slope of Phase III and/or closing volume 
are conflicting. Cosio et al (1978), for instance, found a good corre-
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Figure 3 Closing volume measurement by the single-breath N2 washout 
technique. 
Phase I: dead space gas; phase II: gas from dead space and 
alveolar gas; phase III: alveolar gas ("plateau"); phase IV: 
closure of small airways in the dependent lung zones, while 
upper lung zones, with a high N2-concentration, are still 
emptying. Closing volume (CV) is defined as the volume above 
RV at which phase IV begins. 
lation between pathological and physiological changes In a group of 
36 patients undergoing thoracotomy of whom 34 were smokers. Berend et 
al (1981b) on the contrary, were not able to demonstrate such a cor-
relation. They suggested that these differences may be the result of a 
different method of fixation of the excised lungs-
Although the simplicity of this method seems to be an advantage, 
the performance has to be done very properly, otherwise the within-
subject variability will be too high (McFadden et al, 1975), especial-
ly when this method Is to be used to detect differences in effects of 
bronchodilator and/or bronchoconstrictor agents on small airways func-
tion. 
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3.3.2. Frequency dependence of compliance 
Lung compliance Is a measure of the distensibillty of the lungs and It 
is defined as the change in lung volume per unit change in transpulmo-
nary pressure. This pressure difference between mouth and pleural 
space is measured with a balloon in the lower part of the esophagus. 
At the same time, the change in volume is measured at the mouth from 
which the change in lung volume can be derived. By plotting change in 
lung volume (Δν) against change in transpulmonary pressure (ΔΡ) pres­
sure-volume (P-V) curves are constructed from which lung compliance 
(Δν/ΔΡ) can be calculated. Static lung compliance can be determined 
from P-V curves when airflow is zero. Since this is difficult to per­
form, usually the semistatic compliance is measured by making a slow 
expiratory vital capacity manoeuvre. From P-V curves during different 
breathing frequencies dynamic compliance can be determined. 
Frequency dependence of dynamic lung compliance was first described 
by Woolcock. et al (1969) as a sensitive method to discover small air­
ways dysfunction when routine lung function tests are within normal 
limits. They reasoned that, if static lung compliance (C
s t) as deter­
mined by the static pressure-volume curve, and total pulmonary resis­
tance are normal, a fall in dynamic compliance (С^уп), expressed as 
the ratio C^yn, with increasing respiratory frequency will be the 
Cst 
result of an increasing abnormality in ventilation distribution in the 
lung, which may well be caused by small airways obstruction. They 
showed that in bronchitic and asthmatic patients С^у
п
 was frequency 
dependent in contrast to normal subjects and remained so, though to a 
lesser extent after a (J-adrenoceptor agonist. Later on, several other 
authors (Rubin et al, 1974; Gelb and Zamel, 1973; Martin et al, 1975) 
have used the assessment of frequency dependence of C¿„n as a test for 
small airways obstruction. It appears to be a very sensitive test to 
detect early pathological changes in peripheral airways (McFadden et 
al, 1974; Buist, 1984). 
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3 . 4 . THE FLOW-VOLUME CURVE 
3.4.1. Introduction 
The assessment of small airways obstruction with tests like the fre-
quency dependence of compliance and the measurement of closing volume 
has one major objection: abnormal results obtained with these tests 
are only indicative for small airways disease in the presence of nor-
mal values for elastic lung recoil (i.e. normal static compliance), 
FEV^, specific airways conductance and other parameters of large air-
ways function. By measuring flow and volume during a maximal expira-
tion manoeuvre (MEFV-curve), especially with the use of gases of dif-
ferent densities and viscosities, it became possible to determine 
changes in small airways function even when routine lung function 
tests are abnormal (McFadden and Ingram, 1982). 
While with spirometry lung function is measured by recording In-
and/or exhaled volume against time, lung function can also be assessed 
by plotting flow (V in 1/sec) against volume (V in 1), which yields 
the flow-volume curve. Usually flow and volume are recorded during 
a forced vital capacity manoeuvre. Parameters obtained from this MEFV 
curve are determined by lung elasticity and mechanical properties of 
the intrathoracic airways like static dimensions and dynamic narrowing 
during expiration (Mead et al, 1967; Ingram and McFadden, 1977; Pride, 
1979). 
Changes in calibre of extrathoracic airways do not influence the 
late expiratory part of the MEFV-curve. An example of a MEFV-curve is 
shown in Fig 4 (next page). The inspiratory part of the curve (lower 
panel) is mostly determined by abnormalities in structure and/or func-
tion of the upper(extrathoracic) airways. As we are mainly interested 
in responses of the intrathoracic airways to 6-adrenergic agents, this 
inspiratory part of the curve will not be discussed further. 
3.4.2. The composition of the MEFV-curve 
The MEFV-curve can be divided Into two phases (Schilder et al, 1963; 
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Knudson et al, 1976a/b; Bouhuys, 1977); an Initial effort dependent 
phase which comprises the first 20 to 30% of the expired forced vital 
capacity (FVC) after inhalation to TLC-level. PEFR and to a certain 
extent also FEV^, are determined during this phase. This phase of 
expiratory flow is mostly dependent on the effort of the expiratory 
muscles and resistance of the total pulmonary system (Schilder et al, 
1963). The second phase of the MEFV-curve demonstrates the expiratory 
V(l/i*c) FEV! 
TLC 
VII) 
RVlevtl 
Figure 4 Maximal expiratory flow-volume curve. 
For abbreviations see list of abbreviations (page 13). 
flow of the late two-third part of the FVC and is less effort depen-
dent. MEF50 and MEF25, being the maximal expiratory flow when 50% and 
25% of the FVC respectively, still have to be expired, are the main 
parameters of this phase (Fig 4). This late phase of expiratory flow 
is mainly determined by elastic lung recoil, properties of the res-
pired gas and resistance of smaller airways (Schilder et al, 1963; 
Mead et al, 1967). Especially the flow at lower lung volumes as repre-
sented by MEF25, is thought to reflect small airways function (Mead et 
al, 1967). As acute changes in lung elasticity are rare (Gold et al, 
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1967; Pride, 1979), short-term changes in MEF50 and MEF25 ЬУ broncho-
constrictor or bronchodllator agents are indicative for changes in 
small airways calibre (Bouhuys et al, 1969). 
There is still some discussion on the best method of reading the 
MEFV-curve with regard to the amount of curves which have to be per­
formed and from which curve the parameters should be recorded. Most 
authors (Peslin et al, 1979; Schrader et al, 1983; Johansen and Vale, 
1984) agree that three consecutive curves are sufficient. Parameters 
can be derived from the "envelope-curve", which means that the curves 
are superimposed, preferentially at TLC level, and one composite curve 
is constructed (Peslin et al, 1979; Schrader et al, 1983). The Ameri­
can Thoracic Society on the other hand has proposed that all indices 
should be taken from the curve yielding the largest sum of FVC and 
FEV! (Gardner, 1979). 
3.4.3. Methods for assessing expiratory flow-volume curves 
3.4.3.1. Spirometry 
Spirometers record expired volume against time. From these curves 
flow rates can be obtained by differentiation (Bouhuys, 1977). The 
inertia of a spirometer, however, is usually too high to record high 
flow rates correctly. 
3.4.3.2. Pneumotachography 
With pneumotachography it is possible to measure instantaneously air­
flow and volume (Dawson, 1982; Teculescu, 1985). The pneumotachograph 
consists of a bundle of narrow parallel tubes ("Fleisch") or a fine 
mesh metal gauze ("Lilly"), placed in the airstream. This causes lami­
nar flow and a resistance to airflow which has to be minimal, though 
sufficient enough to induce a pressure-gradient across the resistance. 
This pressure difference is measured by a differential pressure trans­
ducer, and from the output signal flow and volume (integrated flow) 
can be deduced and plotted against each other on an oscilloscope or X-
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Y recorder. For laminar airflow the pressure gradient (ΔΡ) is defined 
by the Poiseuille equation: ΔΡ • β.Ι.η.^ 
Пг4 
wherein Φ » flow of the gas; 
Л » viscosity of the gas; 
1 - length of tube j whereover ΔΡ is measured. 
r » radius of tube ] 
As can be concluded from this equation, a linear relationship 
exists between the pressure difference (ΔΡ) and airflow (V). This 
linearity, however, is only valid when flow is laminar. 
When airflow becomes turbulent, the pressure-flow relationship be­
comes curvilinear. Contrary to laminar airflow, turbulent flow is not 
only dependent upon viscosity of the gas but also upon the density of 
the gas. The flow above which turbulence occurs can be deduced from 
the Reynolds number: Re » 2 ν r ρ 
η 
where ν • velocity of flow; 
Ρ » density; 
Л • viscosity of the gas; 
г » radius of the tube. 
Above or below a critical value of the Reynolds number gas flow 
becomes turbulent or laminar respectively. For instance for airflow in 
a long smooth-walled cylindrical tube the critical value of Re is 
2000. 
When turbulence occurs the Rohrer equation can be applied: 
ΔΡ » ki Φ + k.2 Φ in which к^ and k2 are constances related to visco­
sity and density of the gas respectively. As can be seen from this e-
quation the resistance is proportional to the flow squared and there­
fore considerably higher than in laminar flow. 
When applying these pressure-flow relationships to the airflow in 
the airways difficulties arise, because in the bronchial tree with its 
branches and irregular surface varying airflow profiles develope. In 
the upper, extrathoracic airways there exists a very complex flow pat­
tern. In the trachea and the large bronchi airflow is presumed to be 
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mainly turbulent during forced expiration. In the smaller bronchi 
(down to the 12th generation) (Bouhuys 1977) the Reynolds number of 
airflow is below 2000 and hence airflow is laminar. From the smaller 
airways down to the alveoli gas is transported by diffusion. 
3.4.4. The phenomenon of density dependence 
Differentiation between airway obstruction in the airways with turbu­
lent flow on the one hand and those with laminar flow on the other 
hand became possible by the introduction of measuring MEFV-curves 
when breathing gases with different densities and viscosities. 
Changes in density of the respired gas have their largest effects 
on that part of the MEFV-curve which is limited mostly by turbulence, 
i.e. that part with the highest linear velocity: PEFR and FEV^. Conse­
quently, breathing a gas with low density and high viscosity will 
lower the Reynolds number and airflow becomes more laminar. If, in the 
air breathing situation, the forced expiratory flow was predominantly 
limited by turbulence in the larger airways, then the same manoeuvre 
with a low-density gas will yield much higher peak flow rate and FEV^ 
values. However, if the forced expiratory flow is limited by obstruc­
tion in the peripheral airways (where no turbulence occurs in any 
situation) a low-density gas will not change the forced expiratory 
flow parameters very much. 
Since the slopes of the MEFV-curve around PEFR and FEV^ are very 
steep, small changes in horizontal position of these parameters on the 
MEFV-curves will have tremendous effects when comparing curves breath­
ing air and a low-density gas. Therefore, parameters in the less steep 
parts of the MEFV-curves are compared: MEF50 and MEF25· The difference 
in flow between two gases with different densities is called "density 
dependence"(Ingram and McFadden, 1977; Teculescu et al, 19Θ2; Bogaard 
et al, 1982). This density dependence is usually measured by comparing 
MEFV-curves when breathing air on the one hand and when breathing a 
mixture of helium 80% and oxygen 20% ("heliox") on the other hand. He­
lium has an approximately 65% lower density and a 12% higher viscosity 
than air (Schilder et al, 1963; Bogaard et al, 1982). 
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Several authors (Despas et al, 1972; Dosman et al, 1975; Ingram and 
McFadden, 1977) have used the equal pressure point concept (EPP) of 
Mead et al (1967) to explain the phenomenon of density dependence. 
Normally EPP is located in the large airways which have a small com­
bined cross sectional area. Here, airflow is mostly determined by con-
vective acceleration and turbulence with high Reynolds numbers. When 
breathing a gas with a lower density like heliox, Reynolds numbers 
will be lowered and flow becomes more laminar which results in a 
higher flow rate· This appears to be the case in normal subjects and 
in patients with an obstruction in the larger airways. However, in 
patients whose airflow resistance is mainly located in small periphe­
ral airways, the EPP has moved upstream to the periphery 
of the lung, where the total cross sectional area of the airways 
is large and Reynolds numbers are low resulting in an airflow pat­
tern which is mainly laminar. Now, breathing a gas with a low density 
will not influence the flow pattern and density dependence will not 
occur or be low. Two examples of MEFV-curves breathing heliox superim­
posed on MEFV-curves breathing air are shown in Figure 5. 
V(l/s»e) V(l/sic) 
TLC FVC RV 
V(l) 
TLC FVC RV 
V(l) 
Figure 5 Two examples of MEFV-curves breathing air (—) and a helium 
oxygen mixture ( ). 
A represents a positive density dependence ("responder"): 
MEF50 »20% and V i e o ^ >80Z of the FVC. 
В represents a low density dependence ("non-responder"): 
MEF50 «20% and V l s o γ <80% of the FVC. 
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The parameters derived from this combined curve are: 
1. the increase in MEF50 after heliox as compared to MEF50 breathing 
air. 
2. the volume of isoflow. 
Ad 1) The increase in MEF50 after heliox (MEF50 НеОг) in comparison 
with the MEF50 breathing air (MEF50 air) is usually expressed as 
the ratio MEFsn He07 - MEFsn air x ^ 0 % - ÛMEF 
MEF50 air 5 0 
According to Despas et al (1972) an increase in ДМЕГзо of more than 
20% is called a positive density dependence. They, and later on Dosman 
et al (1975), discovered that normal subjects and some patients with 
CNSLD had а ДМЕРзо of more than 20% and they are called "responders", 
while other patients with CNSLD or smokers had a lower ДМЕГзо and 
therefore are called "non-responders". ÄMEF25> being the increase in 
MEF25 after breathing heliox is less frequently used. 
Ad 2) The volume isoflow (V^so $): this is the lung volume at which 
respiratory flow is the same with air as with the heliox mixture 
(Hutcheon et al, 1974; Dosman et al, 1975). During this part of the 
MEFV-curve airflow is independent of the density and viscosity of the 
respired gas. V^so ψ is usually expressed as a percentage of the FVC 
(Viso φ/FVC). 
Both parameters have been used a) to detect early changes in peri­
pheral airways dysfunction as caused by smoking in comparison with 
non-smokers (Hutcheon et al, 1974; Dosman et al, 1975; Gelb et al, 
1975); b) to compare asthmatics with patients with irreversible air­
ways obstruction (Despas et al, 1972) and с) to study the effects of 
bronchoconstrictor and bronchodilator agents on large and small air­
ways function (Chan-Yeung, 1976; Chick and Jenne, 1977; Brown et al, 
1977; Douglas et al, 1979; Ashutosh et al, 1980; Minette et al, 
1985). 
The effects of constrictor and dilator stimuli on central or more 
peripheral airways can be differentiated by means of the density de-
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pendence (ДМЕРзо) as shown in the following diagram (Ingram and McFad-
den, 1977; Ashutosh et al, 1980; Minette et al, 1985). 
When bronchoconstrlction is mostly located in small airways AMEF5Q 
will be low, whereas ДМЕРзо will be higher when the airflow limitation 
is situated in larger airways. 
Bronchoconstrlction 
Bronchodilatation 
AMEFJO i 
peripheral airways » 
central airways 
central airways > 
peripheral airways 
ДМЕРзо t 
central airways > 
peripheral airways 
peripheral airways > 
central airways 
When ДМЕРзо Is lower after than before administration of a broncho-
dilator agent, it means that central airways are dilated and there is 
still an increased resistance in the peripheral airways. Conversely, 
this can be said when ДМЕРзо rises after bronchodilatation. 
Proportionately equal dilatation of central and peripheral airways 
is thought to be associated with an Increase in expiratory flow parame­
ters like FEVi, MEF50 and MEF25, but no change in ДМЕРзо (Ingram et 
al, 1977). 
3.4.5. The reproducibility of the MEFV-curve 
With regard to the reproducibility of the different parameters which 
can be assessed from the MEFV curve, a distinction should be made be­
tween intersubject and intrasubject variability. According to Quanjer 
(1983) the variation coefficient of the Intersubject variability appro­
ximates 30Z, while for the intrasubject variability he mentions a coef­
ficient of variation of 5%. Other authors have described a higher with­
in-subject variability (McCarthy et al, 1975; Becklake and Permutt, 
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1979). FEV;L and FVC are the most reproducible parameters of the MEFV-
curve; PEFR and MEF50 are less repeatable, but more than MEF25· Looking 
at intrasubject variability in our own studies of parameters of MEFV-
curves during breathing air or heliox, we found coefficients of varia­
tion which are compatible with those cited in literature (Fig. 2). 
As the second part of the MEFV-curve Is supposed to be effort-inde­
pendent, it should be more reproducible than the first, effort-depen­
dent phase (Fig 4). This is, however, not true (Fig 2); several sour­
ces of variability have been mentioned to explain the greater variabi­
lity in MEF50 and MEF25 (Clement and Van de Woestijne, 1971): 
- failure to achieve maximum flows early in expiration; 
- problems with reaching the same maximum inspiratory level; 
- oscillations of maximum flows; 
- some degree of effort-dependency of the second phase. 
With respect to the reproducibility of the phenomenon of density de­
pendence, it can be concluded from the literature, that while MEF50 
measurements when breathing normal air and MEF50 when breathing heliox 
appear to be fairly reproducible, the variability of the relationship 
between these two parameters expressed as density dependence (ДМЕРзд) 
is large, as would be expected on mathematical grounds (Bonsignore et 
al, 1980; Mac Donald and Cole, 1980). 
Berend et al (1981) found a within-subject coefficient of varia­
tion for V j
s o
 ψ of 65.2% in 10 healthy non-smoking volunteers, who 
were studied on three consecutive days and on a day one month later. 
For this last parameter the inter-observer variability was also 
higher than for MEF50 and ДМЕКзо· The reproducibility of ДМЕГзо can be 
enhanced by matching MEFV-curves at TLC level instead of RV level (Jo-
hansen and Vale, 1984). 
However, from our own data, as summarized in Figure 2, it appears 
that the variability of parameters of the MEFV-curve is acceptable, 
when these curves are used to compare ventilatory effects of pharmaco­
logical agents in patients with CNSLD, but only if each patient serves 
as his own control. 
A good repeatability of the maximal airflow at large and low lung 
volumes is important, because assessment of MEFV-curves Is an easy 
performed method to detect calibre changes In central and peripheral 
airways. 
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3.4.6· The partial flow-volume curve 
The maximal Inspiratory manoeuvre preceding the maximal expiration to 
obtain a MEFV-curve can Influence bronchomotor tone as has been men-
tioned In paragraph 3.2.3. In order to abolish the bronchodllator or 
constrictor effects of a maximal Inspiratory manoeuvre, partial expi-
ratory flow-volume curves (PEFV-curves) have been proposed to study 
the airway responses to pharmacological agents and In other bronchial 
challenge tests (Bouhuys et al, 1969; Barnes et al, 1981; Zamel,1984). 
This method Is suitable to study effects on small airways, especially 
In normal subjects or patients with mild asthma (Barnes et al, 1981). 
Barnes and coworkers (1981) demonstrated that in normal subjects PEFV-
curves show greater responses than MEFV-curves and that these PEFV-
curves were relatively good reproducible within each Individual with 
coefficients of variation of 3 to 12%. In asthmatic patients, however, 
PEFV-curves appear to offer no advantage over MEFV-curves for the de-
tection of responses to bronchodilators such as S2_adrenoceptor ago-
nists (Berry and Fairshter, 1985). 
3.5. CONCLUSIONS 
With regard to the assessment of the effects of 0-adrenoceptor ago-
nists and antagonists it is not easy to determine which "test is 
best". In many lung function laboratories the choice is to a certain 
extent determined by the presence of measurement facilities. Measu-
rement of airway resistance with the Plethysmographie method or by the 
forced oscillation technique has the advantage of being easy for both 
investigator and patient. These methods are, however, extremely sensi-
tive and do not discriminate between extra- and intrathoracic airways 
or effects on large or small airways. Measurement of forced expiratory 
airflow is the most often used method, either by spirometry or by 
flow-volume curves. Assessment of FEV^ is probably the most reproduci-
ble and most specific parameter, though not the most sensitive. Never-
theless, the FEVi can be regarded as the gold standard for measurement 
of ventilatory responses of pharmacological agents in patients with 
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CNSLD. PEFR measurement has the great advantage of the simplicity of 
the apparatus, the effort dependence and false high readings due to 
airway compression are, however, disadvantages· Flow-volume curves 
have the great advantage that from one expiratory manoeuvre several 
lung function parameters can be obtained. Also a distinction between 
effects of drugs on large or small airways function can probably be 
derived from the flow-volume curve. Density dependence of airflow is 
increasingly used to discriminate between large and small airways 
function. The large inter- and intrasubject variability of this expi-
ratory flow parameter, however, remains problematical. 
Changes in lung function due to the administration of $-adrenocep-
tor agonists or -antagonists are usually assumed to reflect changes in 
airway smooth muscles. As these drugs do not only have an effect on 
the ^-adrenoceptor of the smooth muscles, it should be realised that 
changes in airway calibre can also be caused by effects of these drugs 
on other 9-adrenoceptor containing cells in the airways or by reflex 
mechanisms, as is described in Chapter 2. In-vitro functional studies 
and receptor binding studies elucidate the mechanisms of 3-adrenocep-
tor function more basically, lung function measurements, however, re-
main, for the time being, the only practical method for assessing g-
adrenoceptor function of the airways in living man. 
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SUMMARY 
In a double blind, placebo-controlled study the ventilatory effects 
of the 0i-selective receptor blockers blsoprolol (EMD 33512) and me-
toprolol and their interactions with the S2 _ a d r e n o c eP t : o r agonist ter-
butaline were investigated in 8 asthmatic patients. Both ß-blockers, 
in all the doses given, caused a significant decrease In peak expira-
tory flow rate (PEFR). Vital capacity (VC) and forced expiratory vo-
lume in one second (FEV^) were significantly decreased only after 10 
mg blsoprolol. Terbutaline inhalation caused the same significant im-
provements in FEVi and PEFR during placebo as during blsoprolol 10 
mg, blsoprolol 20 mg and metoprolol 100 mg. both ß-blockers caused 
equal changes in heart rate (HR) at rest. Systolic and diastolic 
blood pressure (BP) decreased significantly after blsoprolol 20 mg 
and metoprolol 100 mg, but not after blsoprolol 10 mg. Inhalation of 
terbutallne up to a dose of 3.5 mg had no influence on HR and BP. The 
results point to good Βχ-selectivity of blsoprolol 10 mg and 20 mg 
and metoprolol 100 mg in asthmatic patients. No correlation was found 
between the plasma levels of the 0-Ыоскег and the changes in the 
ventilatory indices, HR or BP. 
Keywords: asthma, 3i-selective blockers, blsoprolol, metoprolol; 
terbutallne inhalation, ventilatory effects, plasma levels. 
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INTRODUCTION 
A well-known side effect of 0-receptor antagonists Is an increase in 
bronchospasm in asthmatic patients. Since the introduction of S^-se-
lective receptor blockers this problem has become less serious, not 
only because their influence on lung function is limited, but also be­
cause the bronchodilator effects of f$2~ r e c eP t o r agonists are not inhi­
bited (Johnsson et al, 1975a; Greefhorst and Van Herwaarden, 19Θ2). 
It has been shown in animal experiments and in studies on human vo­
lunteers that the recently developed 3-receptor blocker blsoprolol 
has a high degree of ß^-receptor selectivity (Manalan et al, 1981; 
Leopold et al, 1982). The aim of the present study was to assess the 
B^-receptor selectivity of blsoprolol in comparison with metoprolol 
and placebo by investigating the effects of these drugs on lung func-
tion in asthmatic patients. Interaction with the bronchodilator effect 
of a 02 - r e c eP t o r agonist was also studied. Since the Bi-receptor se-
lectivity of a @-blocker can diminish in higher dosages, 2 different 
dose levels of blsoprolol were administered. 
PATIENTS AND METHODS 
The study comprised 8 male patients with bronchial asthma, defined as 
paroxysmal, reversible, generalised, airway obstruction. Three of 
these patients also suffered from chronic bronchitis, with complaints 
of coughing and sputum expectoration. Clinical details of the pa-
tients are listed in Table 1 (next page); their mean age was 39 yrs, 
mean height 173 cm and mean weight 74.9 kg. Four patients had atopic 
extrinsic asthma with one of more positive skin tests. All patients 
were in a stable respiratory state, which means that there had been no 
respiratory infection or increase in bronchoconstriction within the 4 
weeks before the study. Direct bronchodilators, such as theophylline 
and 02 - r e c eP t o r stimulating drugs, were discontinued at least 4 days 
prior the the study; 3 patients continued using disodium cromoglycate 
without changing the dose during the study period. The mean forced ex-
piratory volume In one second (FEV^) was 2.34 1, i.e. 50% or more of 
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Table 1. Patient characteristics. 
Subject Age Asthma Height Weight 
(years) type* (cm) (kg) 
FEW ι 
Actual Ζ of % increase 
(L) predicted with 
values terbutaline 
* E - Extrinsic I • intrinsic CBr · chronic bronchitis 
**C • disodium cromoglycate Th - theophylline derivatives, F - fenoterol, S 
treatment 
for COLD** 
1 
2 
3 
4 
5 
6 
7 
β 
mean+SEM 
31 
43 
49 
24 
40 
52 
36 
35 
39+3 
E 
I + CBr 
I + CBr 
E 
E 
I + CBr 
I 
E 
185 
161 
166 
175 
178 
172 
176 
169 
173+3 
70.0 
73.0 
79.0 
62.5 
93.0 
77.3 
88.1 
56.2 
74.9+4.3 
2.80 
1.55 
2.00 
2.90 
2.50 
1.85 
3.10 
2.00 
2.34+0.20 
61 
50 
63 
67 
63 
55 
77 
54 
35 
22 
20 
19 
36 
24 
19 
45 
С Th 
F Th 
-
-
С 
-
S 
С 
salbutamol 
the predicted normal value (Quanjer 1983), and In all patients the 
FEVi increased more than 15% after stimulation with the ß2 - r e c eP t o r 
agonist terbutaline (Table 1). 
Patients with cardiovascular diseases other than arterial hyper-
tension were excluded from the study. All the patients gave their 
written informed consent to it. The design of the study was approved 
by the Ethical Committee of the Medical Faculty of the University of 
Nymegen. 
The investigations were performed on 4 different days, separated 
by intervals of at least 2 days to serve as washout periods. Placebo 
was given single blind on the first day. On the following days the 
patients received, double blind and in random order, bisoprolol 10 
mg, bisoprolol 20 mg or metoprolol 100 mg. All measurements started 
at 11.30 h in order to minimize variation in baseline lung function 
and to avoid the morning dip, which frequently occurs in asthmatic 
patients (Connolly 1979). The 0-blockers were administered orally 
before a standard meal to avoid differences in bioavailability within 
each individual (Melander 1977). Before and 120 min after intake of 
the medication the following indices were measured: FEV^, Inspiratory 
vital capacity (VC; Godart Pulmotest, highest of three readings) and 
PEFR (Wrightpeak flow meter, highest of two readings); the HR was 
recorded with an electrocardiograph (Heilige); and the BP was assess-
ed with the automatic blood pressure device Physiometrics 5R2. Next, 
a dose-response curve with the 02 - r e c eP t o r agonist terbutaline was 
determined by measuring the ventilatory indices, HR and BP, 15 min 
after inhalation of increasing dosages. Terbutaline was inhaled from 
a metered dose aerosol, each puff containing 0.5 mg terbutaline sul-
phate (Draco, Sweden), in cumulative dosages of 0.5 mg,1.5 mg and 3.5 
mg. At 2 h and 3 h 15 min after drug intake, a blood sample was col-
lected for determination of the plasma levels of the ß-blockers. The 
plasma levels were measured by HPLC (E. Merck, Darmstadt, FRG), in 
samples stored at -20°C until analyzed. 
All results are presented as mean + SEM. Statistical analysis was 
performed with the Wilcoxon test for paired observations. Statistical 
significance was defined as p<0.05. 
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RESULTS 
There were no significant differences in ventilatory indices, HR and 
BP, measured before drug intake on the 4 study days- The changes in 
ventilatory indices 2 h after intake of the tablets are presented in 
Table 2 (next page ) and Fig. 1. 
Δ systolic blood pressure Δ diastolic blood pressure 
(mm Hg) 
0 
-10 
- 2 0 
-30 
Δ heart rote 
( btats/min) 
Ля 
ψ.ϊ 
о 
-10 
-20 -
(mm Hg) 
•Ρ < 0.05 
• · Ρ < 0.01 
0 Placebo 
Η Bisoprolol 10 mg 
Ξ Bisoprolol 20 mg 
Ξ Metoprolol!00 mg 
Figure 1. Changes in blood pressure, heart rate and FEV^ 2 h after 
intake of placebo, bisoprolol 10 mg and 20 mg, and meto-
prolol 100 mg (mean + SEM; n-8). 
Both ß-blockers caused a significant decrease in PEFR. The decrease 
in FEVj was significant at the 1% level for bisoprolol 10 mg, but not 
for bisoprolol 20 mg or metoprolol 100 mg. The VC decreased signifi-
cantly only after bisoprolol 10 mg. There were no significant diffe-
rences between the changes in ventilatory indices induced by these B-
blocking agents 2 h after drug intake. 
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Table 2. Ventilatory Indices before and after ingestion of placebo, blsoprolol and metoprolol 
and after Inhalation of cumulative doses of terbutallne (шеап+SEM; n-8). 
FEV! (L) 
placebo 
blsoprolol 10 
blsoprolol 20 
metoprolol 100 
PEFR (L/mln) 
placebo 
blsoprolol 10 
blsoprolol 20 
metoprolol 100 
VC (L) placebo 
placebo 
blsoprolol 10 
blsoprolol 20 
metoprolol 100 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
•g 
Initial 
value 
2.33+0.19 
2.4Э-Ю.17 
2.34+0.17 
2.47+0.23 
338 +22 
351 +18 
348 +14 
358 +24 
3.93+0.33 
4.04+0.27 
3.99+0.31 
4.09+0.33 
2 hours 
after drug 
intake 
2.21+0.18 
2.10+0.18 
2.18+0.20 
2.20+0.18 
329 +18 
301 +20 
298 +19 
291 +23 
3.86+0.33 
3.78+0.28 
3.88+0.31 
3.88+0.28 
Ρ* 
NS 
«0.01 
NS 
NS 
NS 
«0.01 
«0.02 
«0.02 
NS 
«0.02 
NS 
NS 
terbutallne 
0.5 mg 
2.69+0.23 
2.59+0.18 
2.52+0.17 
2.54+0.22 
382 +23 
376 +20 
366 +12 
362 +23 
4.06+0.31 
4.09+0.31 
4.03+0.29 
4.09+0.29 
P** 
«0.01 
«0.01 
«0.02 
NS 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
NS 
«0.05 
1.5 mg 
2.90+0.25 
2.88+0.24 
2.81+0.22 
2.77+0.23 
403 +23 
402 +23 
393 +16 
387 +28 
4.13+0.31 
4.19+0.31 
4.19+0.33 
4.13+0.28 
P** 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.05 
«0.02 
3.5 mg 
2.96+0.24 
2.98+0.24 
2.88+0.24 
2.91+0.25 
410 +20 
416 +23 
405 +19 
409 +23 
4.24+0.33 
4.21+0.32 
4.13+0.32 
4.24+0.31 
p** 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
NS 
«0.01 
p-value 2 h after drug Intake versus Initial value 
ρ"» p-value versus 2 h after drug intake 
NS not significant 
r > * * 
Inhalation of terbutaline In increasing doses led to significant 
stepwise improvements in FEV^ and PEFR (Table 2 [page 69], Fig. 2 
[page 71]). The effect of terbutaline on the indices was of the same 
magnitude after bisoprolol 10 mg and 20 mg and metoprolol as after 
placebo. The Improvements in VC were less pronounced (Table 2). 
Both ß-blocking agents caused a significant decrease in HR 2 h af-
ter administration (Fig. 1). The systolic and diastolic BP declined 
significantly after intake of bisoprolol 20 mg and metoprolol 100 mg, 
whereas the decrease after bisoprolol 10 mg was not significant. No 
change in these values after placebo was observed. Inhalation of ter-
butaline had no influence on HR and BP (Fig. 3) (page 72). 
The plasma levels of the B-blockers are presented in Table 3. The 
plasma levels of bisoprolol 10 mg and bisoprolol 20 mg remained con-
stant between 120 and 195 min after drug intake- The plasma metopro-
lol level, however, decreased significantly over that period. 
Table 3. Plasma level of bisoprolol after 10 and 20 mg doses and of 
metoprolol after 100 mg (ng/ml) 2 h and 3 h 15 min after 
drug intake (mean + SEM; n-8). 
bisoprolol bisoprolol metoprolol 
10 mg 20 mg 100 mg 
78 + 15 
34 -155 
54 + 19 
21 - 96 
120 min 
range 
195 min 
range 
120 min 
versus 
195 min 
4 5 + 6 
15 - 65 
4 2 + 4 
25 - 66 
NS 
8 3 + 6 
62 -107 
8 0 + 5 
67 -110 
NS 
ρ < 0.05 
70 
PEFR »20 
(l/mm) 
• placebo 
O blsoprolol 10 mg 
• blsoprolol 20 mg 
D metoprolol 100 mg 
120 US 170 
time (mm) 
Flg. 2 Changes In FEV^ and PEFR Induced by Inhalation of 
terbutallne In cumulative doses after placebo, 
blsoprolol 10 mg and 20 mg, and metoprolol 100 mg. 
71 
BP tptel ic 
(mm Hg) 
BPtaitolK ' 0 
(mmHg) 
HR (btott/min) 
0 5mg 
- P -
• placebo 
О bisoprolol 10 mg 
• bisoprolol 20 mg 
Π metoprolol 100 mg 
3 5mi 
/ ttrbutolm· 
HO HS 170 1(S 
l i m · (mm) 
Flg. 3 Effect of Inhalation of terbutallne In cumulative doses 
on blood pressure and heart rate after placebo, 
bisoprolol 10 mg and 20 mg, and metoprolol 100 mg. 
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DISCUSSION 
The study was performed In asthmatic patients with an Increase In FEV} 
of more than 15% after administration of terbutallne- It was necessary 
to study patients with this type of reversible airway obstruction, be-
cause In asthmatic patients with low reversibility 0-blockers have no 
appreciable effect on airway obstruction. The latter type of patient 
Is unsuitable for study of the ß^-receptor selectivity of B-blockers 
(Nordström et al, 1975; Perks et al, 1978). 
It has been demonstrated that metoprolol caused bronchoconstrlctlon 
In asthmatic patients, which Is completely reversible with a 02-recep-
tor agonist, Indicating the P^-receptor selective character of meto-
prolol (Johnsson et al, 1975a; Greefhorst and Van Herwaarden, 1982). 
Animal studies and work In healthy human volunteers have shown that 
blsoprolol Is a 0-receptor antagonist with a high degree of B^-recep-
tor selectivity and, like metoprolol, it lacks partial agonist activi-
ty (Manalan et al, 1981; Leopold et al, 1982). As blsoprolol 10 mg and 
metoprolol 100 mg are equivalent in terms of their effect in reducing 
exercise-induced tachycardia (Leopold et al, 1982), the effect of 
these doses was compared. A study was also made of whether the effect 
of blsoprolol was enhanced when the dose was raised to 20 mg, because 
it is known that at higher dosages βχ- receptor-selective antagonists 
can also block 0 2 ~ r e c e P t o r 8 (Lertora et al, 1975). 
In the present study blsoprolol 10 mg and 20 mg and metoprolol 100 
mg caused the same significant reduction in HR at rest. BP decreased 
significantly after blsoprolol 20 mg and metoprolol 100 mg (Fig. 1). 
Inhalation of the 02-receptor selective agonist terbutallne had no 
effect on HR and BP. 
Both ß-receptor blockers caused an increase in bronchoconstrlctlon, 
as shown by a decrease In PEFR. It was not possible to demonstrate a 
dose-related effect of blsoprolol on lung function. 
The improvement in lung function after inhalation of terbutallne 
was similar for blsoprolol, metoprolol and placebo (Fig. 2). The dose 
response curve for a ß2-receptor agonist In patients on 8-receptor 
blockade gives information on the degree of selectivity of the 0-re-
ceptor blocker. During nonselective i-receptor blockade, the curve 
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shifts to the right as compared with а ß^- receptor selective blocker 
and placebo, as a consequence of blockade of 02" receptors in the 
airways (Johnsson et al, 1975a; Greefhorst and Van Herwaarden, 1982). 
The results indicate similar ß^-receptor selectivity for blsoprolol 
and metoprolol, because the positions of the dose-response curves 
were the same after both 0-receptor blockers. 
The effects on lung function of these Ö^-receptor selective anta-
gonists can be explained in two ways: the 0-blockers are not comple-
tely βχ-receptor-selective, or the airways also contain functional 
0|-adrenoceptors. Further studies are needed to solve this question. 
Plasma levels after blsoprolol 20 mg were twice as high as those 
after blsoprolol 10 mg, which is in accordance with the doses admi­
nistered and the known pharmacokinetics of this drug (Leopold et al, 
1982). There was only a minor change in plasma blsoprolol level be­
tween 2 h and 3 h 15 min after drug intake, whereas the plasma level 
of metoprolol decreased significantly over the same period (Table 3). 
The difference can be explained by the half-lives of the ^-blockers, 
namely 11 and 3 h for blsoprolol and metoprolol, respectively (Johns-
son et al, 1975b; Leopold et al, 1982). No correlation was found be­
tween the plasma levels of the fi-blockers and their effects on the 
ventilatory indices, HR and BP. 
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SUMMARY 
1. Effects of long-term treatment with pindolol (10 mg twice daily) 
and metoprolol (100 mg twice daily) on lung function and blood press-
ure were investigated in eight patients with chronic obstructive lung 
disease and hypertension· 
2· After a placebo period, both 0-adrenoceptor blockers were adminis-
tered double-blind and cross-over for 4 weeks. 
3. By assessing parameters of expiratory flow an attempt was made to 
distinguish between large and small airways function. 
4. Diastolic blood pressure decreased significantly during both pindo-
lol and metoprolol (p<0.01). 
5. Except for a decrease in forced expiratory volume in 1 s (FEV}) 
during metoprolol treatment, there was no other change in expiratory 
flow parameters after placebo or both 0-adrenoceptor blockers. 
6. Inhalation of terbutaline induced a small improvement in large air-
ways function after placebo and metoprolol, but not after pindolol; 
there was no effect of terbutaline on parameters of small airways 
function. 
7. If a 0-adrenoceptor blocker is necessary in patients with chronic 
obstructive lung disease, a 0i-adrenoceptor selective blocker is pre-
ferred in combination with bronchodilator agents. 
Keywords: hypertension, metoprolol, pindolol, chronic obstructive 
lung disease 
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INTRODUCTION 
Ö-adrenoceptor antagonists can Induce or aggravate bronchoconstrictlon 
in patients suffering from chronic obstructive lung disease. The degree 
of airway obstruction induced by 0-adrenoceptor blockers depends on an-
cillary properties of these drugs. It has been demonstrated that ßj-
adrenoceptor selective antagonists such as metoprolol, and 0-adrenocep-
tor blockers with intrinsic sympathomimetic activity such as pindolol, 
have a less detrimental effect on lung function than nonselective 3-
adrenoceptor blockers such as propranolol (Johnsson et al., 1975; Ulmer 
et al., 1976; Ruffin et al., 1982). 
Moreover, the bronchodilator response to a B2 - a^ r e n o c eP t o r agonist 
is blocked by a nonselective B-adrenoceptor blocker, but not by a βχ-
adrenoceptor selective blocker (Benson et al., 1978). 
The untoward ventilatory effects of 0-adrenoceptor blockers in pa­
tients with asthma or chronic obstructive bronchitis are hardly predic­
table, but patients with a low-reversible or fixed bronchial obstruc­
tion generally show no deterioration of lung function during ß-adreno-
ceptor blockade (Perks et al., 1978). 
Most of the above conclusions were based on short-term studies. The 
purpose of this investigation was to determine the ventilatory effects 
of metoprolol and pindolol during long-term treatment in a group of hy-
pertensive patients with chronic obstructive lung disease, while they 
continued bronchodilator therapy. 
METHODS 
Eight patients, seven males and one female, with chronic obstructive 
lung disease and hypertension completed the study. Some clinical de-
tails of the patients are listed In Table 1 (next page)· Seven patients 
suffered from chronic bronchitis, while patient number 7 was an asthma-
tic with several positive skin tests and a low histamine tolerance dur-
ing provocation. These diagnoses were made In accordance with the diag-
nostic standards of the American Thoracic Society (1962). There were no 
patients with emphysema. During bronchodilator therapy the forced expl-
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Table 1 Patient characteristics. 
Subject 
1 
2 
3 
4 
5 
6 
7 
8 
mean 
+ SEM 
Age 
(У) 
44 
52 
59 
60 
62 
49 
35 
60 
52.7 
0.4 
Height 
(cm) 
161 
177 
158 
179 
179 
177 
185 
172 
173.5 
3.3 
Weight 
(kg) 
77 
90 
71 
75 
95 
96 
82 
83 
83.6 
3.3 
TLC* 
(L) 
5.8(103) 
6.7( 94) 
4.9(106) 
7.0( 95) 
8.4(114) 
5.9( 83) 
7.9(100) 
7.0(106) 
6.70 
0.41 
FVC* 
(L) 
3.0( 79) 
4.7(104) 
1.7( 
3.3( 
2.7( 
4.2( 
5.3( 
3.8( 
3.58 
0.41 
65) 
75) 
61) 
91) 
98) 
95) 
FEViiL)* 
before 
terbutaline 
2.2(71) 
3.6(97) 
0.7(31) 
1.9(53) 
1.1(31) 
3.1(79) 
4.2(89) 
2.2(66) 
1.93 
0.42 
after 
terbutaline 
2.2 
3.8 
1.1 
2.1 
1.4 
3.2 
4.7 
2.2 
2.59 
0.43 
MEF50* 
(Ls"1) 
2.3(52) 
3.5(74) 
0.4(11) 
1.0(22) 
0.4( 8) 
3.5(73) 
4.0(71) 
1.4(33) 
2.06 
0.52 
Treatment** 
for chronic 
obstructive 
lung disease 
В F Th 
В S Th 
S Th 
S Th 
В S Th 
S 
С S 
В S 
* values in parentheses: Ζ of predicted normal values (Quanjer, 1983). 
** В - beclomethasone; С - cromoglycate; F - fenoterol; S - salbutamol; Th " long-acting theophylline 
TLC - total lung capacity measured by helium dilution 
FVC - forced vital capacity (L) 
FEV1 - forced expiratory volume in one second (L) 
MEF50- maximal expiratory flow rate at 50Z of FVC (Ls - 1) 
ratory volume In 1 s (FEVj) Improved > 10% in four patients and remain-
ed almost unchanged in the other four patients (Table 1). All patients 
were In a stable respiratory state which means that they had had no 
respiratory Infection or Increase In bronchoconstriction during the 
last month before the study. They continued the medication for their 
chronic obstructive lung disease during the study period in the same 
doses as before the study (Table 1). They were only allowed to increase 
the amount of the inhaled 02-adrenoceptor agonist, which event had to 
be recorded on a symptom diary card. 
Hypertension was defined as a diastolic blood pressure >_ 95 mm Hg 
(measured on three occasions; Korotkoff phase 5). One patient was ac-
cepted with a diastolic blood pressure of 90 mm Hg, while taking a diu-
retic. Patients with cardiovascular diseases other than arterial hyper-
tension were excluded from the study. The study was approved by the 
local Ethics Committee and written informed consent was obtained from 
each patient. The study was designed as a placebo controlled, double-
blind cross-over comparison between pindolol and metoprolol. All pa-
tients were in the trial for 12 weeks. During the first 4 weeks they 
Ingested single-blind a placebo twice a day. Next, they received dou-
ble-blind and cross-over, pindolol 10 mg twice daily or metoprolol 100 
mg twice daily, each during 4 weeks· 
The patients were examined at the out-patient clinic at 2 week in-
tervals. At every visit blood pressure (BP) and heart rate (HR) were 
assessed. After 15 min of rest BP was measured in the supine (two read-
ings) and the erect position with a Hawksley random zero sphygmomanome-
ter. Before the study and after each 4 week period lung function was 
measured with flow-volume equipment (Pneumoscreen No. II, Jaeger). 
Flow-volume curves were plotted on an X-Y recorder (Hewlett Packard 
7045B). Several components of airflow rate and exhaled lung volume were 
assessed with the so-called envelope method: the indices were read on 
the composite curve, obtained by taking the envelope of three Indivi-
dual curves superimposed at TLC level (Peslin et al., 1979). FEV^, 
forced vital capacity (FVC) and peak expiratory flow rate (PEFR) give 
predominantly information on the air flow in the larger airways; the 
maximal expiratory flow rates at 50% and especially at 25% of the FVC 
(MEF50 and MEF25 respectively) are thought to be indicators that are 
81 
more specific of smaller airway conductance 1979). On the morning of 
the lung function measurements the patients did not take $2-a<'renoceP_ 
tor agonists. 
Under this "baseline" condition lung function was assessed for each 
patient at a fixed time of the day in order to minimize diurnal varia-
tion in lung function (Connolly, 1979). Lung function measurements 
were repeated after inhalation of the &2-adrenoceptor agonist terbuta-
line. Terbutaline was inhaled with a metered dose aerosol in cumulati-
ve dosages of 1.0 mg and 2.0 mg. Symptom diary cards which recorded 
diurnal dyspnoea, dyspnoea at night, sleep disturbances and medication 
were completed daily by each patient. Before inhalation of bronchodi-
lator medication, PEFR was recorded twice a day with a Wright mini 
peak flow meter (highest value of three readings). Statistical analy-
sis was performed with the Wilcoxon test for paired observations. Sta-
tistical significance was defined as p<0.05 (Colton, 1974). 
RESULTS 
In comparison with the values during placebo, diastolic BP declined 
significantly during treatment with both pindolol and metoprolol (Table 
2) (next page). There were no statistically significant differences 
between the effects on BP of pindolol and metoprolol. HR decreased 
significantly during treatment with both ß-adrenoceptor blockers; the-
re was no significant difference between the heart rate during pindo-
lol and that during metoprolol (Table 2). 
The daily measured PEFR remained constant throughout the study: 
there were no statistically significant differences between the values 
during placebo and those during both S-adrenoceptor blockers (Table 3) 
(next page). The PEFR did not change during the day: the morning and 
evening values were the same throughout the study. Statistical analy-
sis of the data obtained from the symptom diary cards did not show any 
differences in the pulmonary complaints of the patients between any of 
the three study periods, nor was there any change in the amount of 
bronchodilator medication used. The effect of placebo and both 0-adre-
noceptor blockers on the ventilatory indices measured after each 4 
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Table 2 Blood pressure and heart rate at rest after 4 weeks on placebo 
and 4 weeks of ^-adrenoceptor blockade (mean + s.e. mean, n-8). 
Systolic 
pressure 
(mm Hg) 
supine 
erect 
Diastolic 
pressure 
(mm Hg) 
supine 
erect 
Heart rate 
(beats min"1) 
PLACEBO 
148+5 
145+4 
102+3 
107+4 
78+4 
PINDOLOL 
135+6 
135+6 
91+3 
92+4 
66+2 
P* 
NS 
NS 
<0.01 
<0.01 
<0.05 
METOPROLOL 
134+3 
124+4 
89+3 
90+3 
62+2 
P** 
-0.01 
<0.01 
«0.01 
«0.01 
«0.01 
p*** 
NS 
NS 
NS 
NS 
NS 
p* pindolol versus placebo, p** metoprolol versus placebo, p*** pindolol 
versus metoprolol. NS not significant 
Table 3 Dally measured PEFR (L min-1) after 4 weeks on placebo and 
4 weeks of ß-adrenoceptor blockade (mean + s.e. mean, n-8). 
Morning Evening 
placebo 
pindolol 
metoprolol 
377+53 
360+55 
370+55 
378+48 
357+55 
371+51 
week period are shown in Figures 1 and 2. The baseline FEV^ during me­
toprolol was significantly lower than that during placebo (p « 0.05), 
but did not differ from the baseline FEVj during pindolol (Figure 1). 
FEV, 2 8 
ID 
8 
2 6 -
24H 
2 2 -
ΣΟ­
Ι » -
r*-l 
Τ 
Is 
Τ 
W 
W 1 à 
m 
Γ Ί baseline 
after 1 mg terbulalme 
atler 2 mg lorbulaline 
placebo 
Figure 1. Effects of placebo and 3-adrenoceptor blockade and stimula­
tion with terbutallne on FEVj (L), mean + s.e.mean, n-8. *p<0.05, 
**p<0.01. 
There were no statistically significant differences between the base­
line values of the FVC and PEFR (Figure 2) and of the MEF50 and MEF25 
during placebo and both 3-adrenoceptor blockers. 
Inhalation of terbutallne up to a cumulative dose of 2 mg induced 
a small, but significant increase In FEV^, FVC and PEFR during placebo 
and metoprolol, but not during pindolol (Figures 1 and 2). The MEF50 
and MEF25 values did not change after Inhalation of terbutallne during 
placebo or both S-adrenoceptor blocking agents. 
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Flgure 2. Effects of placebo and B-adrenoceptor blockade and stimu­
lation with terbutallne on FVC (L) and PEFR (Ls - 1), mean + s.e.mean, 
n=8. *p<0.05, **p<0.01. 
DISCUSSION 
BP and HR at rest were effectively lowered by both pindolol and raeto-
prolol In this group of hypertensive patients with chronic obstructive 
lung disease. Dally measurements of PEFR Is actually the only practi­
cal method to assess the lung function of patients at horn (Pride, 
1979). In our patients the dally measured PEFR remained unchanged dur­
ing the placebo period and during treatment with both β-adrenoceptor 
blockers. We could not demonstrate a difference between morning and 
evening PEFR values. All patients were in a stable respiratory state 
before they entered the study and remained so throughout the study 
period. The baseline lung function measurements assessed during the 
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clinical visits, demonstrated a small decrease in FEVj during metopro-
lol, but not during pindolol treatment. The partial agonist activity 
of pindolol probably caused some stimulation of the bronchial B-adre-
noceptors under baseline conditions. The bronchodilator response to 
terbutaline was completely inhibited by pindolol, but not affected by 
raetoprolol. This difference is in accordance with the ßj-adrenoceptor-
selective property of metoprolol and the nonselective character of 
pindolol (Johnsson et al., 1975; Benson et al., 1978). 
This bronchodilation, however, could only be assessed by increases 
in FEVj, FVC and PEFR. There was no change in MEF50 and MEF25 either 
during 0-adrenoceptor blockade or during 3-adrenoceptor stimulation. 
In this group of patients with chronic obstructive lung disease the 
lumen of the larger airways is at least partially dependent on changes 
in smooth muscle tone and sensitive to 0-adrenoceptor modulation. The 
airflow in the more peripheral airways, on the other hand, appeared 
to be insensible to 0-adrenoceptor modulation and is possible more 
dependent on structural changes in the walls of these airways. Patakas 
et al. (1983) demonstrated a decrease in parameters of small airways 
function after a single dose of 2.5 mg pindolol in asthmatic patients, 
while there was no significant effect of pindolol on large airways 
function. As in our patients, however, Dorow et al. (1980) found no 
change in parameters of large and small airways function after admi-
nistration of pindolol to patients with chronic obstructive bronchi-
tis. The difference in effect of pindolol on small airways function 
between these studies might be explained by a difference in patient 
selection, i.e. a difference in reversibility of bronchial obstruc-
tion. Moreover, our patients continued to use their bronchodilator 
therapy. Differentiation between the effects of the used 0-adrenocep-
tor blockers on large and small airways function, however, remains 
difficult, as we have investigated a relatively small group of pa-
tients. By measuring maximal expiratory flow breathing air and a he-
lium-oxygen mixture, it might be possible to obtain a better discri-
mination between the effects of 0-adrenoceptor blockers on large and 
small airways conductance (Bogaard et al., 1982; Despas et al., 
1972). In a future study we will try to elucidate this question. Ne-
vertheless, our data show that the lung function in this group of hy-
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pertenslve patients with chronic obstructive lung disease was virtual-
ly not depressed by metoprolol or pindolol at dosages which ensured a 
good regulation of their hypertension. In comparison with metoprolol, 
however, pindolol inhibited the bronchodllator response to terbutallne 
in the larger airways. If long-term treatment with a B-adrenoceptor 
blocker Is necessary in patients with chronic obstructive lung disea-
se, a ß^-adrenoceptor-selective blocker is preferred In combination 
with bronchodllator agents and under regular control of lung function. 
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SUMMARY 
The cardioequipotency of 400 mg bevantolol and 100 mg atenolol was de-
termined by measuring the exercise heart rate in healthy volunteers. 
The 0-blockers were then used in these doses to investigate their ven-
tilatory effects in patients with asthma. 
The effects of both drugs on forced expiratory flow parameters for 
large and small airways were assessed at rest and during and after ex-
ercise. A dose-response curve was then plotted after inhalation of the 
ß2-adrenoceptor agonist terbutaline. Bevantolol significantly decreas-
ed the forced expiratory volume in 1 second (FEV^) and the peak expi-
ratory flow rate (PEFR) at rest, while there was no such change with 
placebo or atenolol. Both 0-blockers decreased the maximal expiratory 
flow rated at 50% of forced vital capacity (MEF50) and after expira-
tion of 75% of the forced vital capacity (MEF25) at rest; the decrea-
se was larger after bevantolol than after atenolol. During atenolol 
there was a decrease in FEV^ and in PEFR (p«0.01) 15 minutes after 
exercise in comparison with preexercise values. There was no signifi-
cant difference between pre-and postexercise values of MEF50 and MEF25 
during atenolol dosing. After bevantolol there was only a small change 
in PEFR after exercise, probably because of the low preexercise values 
of the ventilatory indices with this drug. Inhalation of terbutaline 
up to a dose of 2 mg significantly improved all ventilatory indices 
measured, but with bevantolol the values after 2 mg inhaled terbuta-
line were lower than the initial values. We conclude that atenolol and 
bevantolol have different effects on large and small airways function 
in patients with asthma and that the effect of exercise on bronchocon-
striction can be enhanced by ß-blockade. 
Furthermore, 100 mg atenolol appears to be more Bi-adrenoceptor-
selective than 400 mg bevantolol. 
INTRODUCTION 
Studies of the ventilatory effects of 0-adrenoceptor antagonists in 
patients with asthma and reversible bronchial obstruction have proved 
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to be good models for assessment of the 0i-adrenoceptor selectivity of 
these drugs'»11. Atenolol has been shown to be a $i-adrenoceptor selec-
tive blocker Inducing a limited decrease In airway conductance that can 
easily be reversed by a 02~ a^ r e n o c eP t o r agonist"·1 . Bevantolol is a 
new ^-adrenoceptor antagonist with 01-adrenoceptor selective effects in 
animals". Our aim was to investigate the 0i-adrenoceptor selectivity of 
bevantolol in comparison with atenolol in patients with asthma. In many 
studies on the effects of 0-blockade on lung function, only parameters 
of large airways function are measured. We were interested whether the 
influence of these drugs on large airways function on the one hand and 
conductance in the more peripheral airways on the other hand would 
differ. 
The effects of ß-blockers on lung function in patients with asthma 
can be enhanced by exercise1^^'»^. This phenomenon is probably caused 
by a more effective 0-blockade during a state of increased sympathetic 
tone. We therefore measured lung function at rest and during exercise-
To compare cardloequlpotent doses of both drugs, we first determined in 
healthy subjects which dose of bevantolol caused the same reduction in 
exercise-induced tachycardia as 100 mg atenolol. 
METHODS 
The study to determine cardioequipotency was carried out in six heal-
thy men 21 to 25 years old. Each subject was studied on 4 days at in-
tervals of at least 1 week; a training effect could thus be discount-
ed. After arrival at the hospital at 9.00 AM, the subjects rested 30 
minutes before the first exercise test began. Each exercise test con-
sisted of 5 minutes of bicycling on an electrically braked ergometer at 
an individually determined load that induced a heart rate of approxima-
tely ISO bpm before drug dosing. After the first test the study drugs 
were taken by mouth. On the first day the subjects took (single-blind) 
a placebo; on the 3 other days they received (double-blind in random 
order) 200 mg bevantolol, 400 mg bevantolol, and 100 mg atenolol. Sub-
sequent exercise tests were performed 1, 2, 3, 5 and 7 hours after dos-
ing. At each test the heart rate was recorded by a continuous ECG trac-
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Ing and blood samples were drawn for determination of the plasma le­
vels of the 0-blockers. Samples were stored at -20oC until analyzed by 
HPLC. 
To compare the ventilatory effects of bevantolol and atenolol, we stu­
died eight men with bronchial asthma . Clinical data of these patients 
are listed in Table I. 
TABLE I Patient characteristics 
Patient 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
X+SE 
Age 
(yr) 
36 
21 
20 
20 
35 
23 
46 
20 
27.6+3, 
Asthaa 
type 
I 
E 
E 
E 
E 
E 
E 
E 
.5 
Height 
(cm) 
176 
178 
177 
185 
177 
171 
164 
180 
176+2.2 
Weight 
(kg) 
85 
61 
62 
73 
73 
62 
62 
60 
67.3+3.1 
FEV! 
Ζ 
Increase 
with 
(L) terbutaline 
3.1(74) 
2.6(55) 
2.7(57) 
3.7(71) 
1.9(45) 
2.3(53) 
2.7(83) 
2.4(50) 
2.68+0.19 
16 
29 
56 
24 
21 
35 
22 
42 
30.6+4.7 
Therapy 
С 
-
С 
-
CBS 
-
в 
CS 
Values in parentheses are the percentage of predicted values." 
E-extrineic; I-intrlnsic; B-beclomethasone; C-cromoglycate; 
S-salbutamol. 
Seven patients had atopic extrinsic asthma with one or more positive 
tests. Two patients (nos. 1 and 5) (Table I), were cigarette smokers 
and the others were nonsmokers. All patients were In a stable respira­
tory state (no respiratory infection or increase In bronchoconstric-
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tion within the past month). Salbutamol was stopped in the two pa-
tients who used this drug regularly at least 2 days before the study; 
four patients continued cromoglycate and two continued beclomethasone 
therapy without a change in dose during the study. In all patients the 
FEVi increased by »15% after stimulation with the 02-adrenoceptor ago-
nist terbutaline. Patients with cardiovascular diseases other than ar-
terial hypertension were excluded. The study was approved by the local 
Ethics Committee and informed consent was obtained from each patient. 
The study was designed as a placebo-controlled, double-blind, 
crossover comparison of single doses of 400 mg bevantolol and 100 mg 
atenolol. Every patient was studied on 3 different days, separated by 
intervals of at least 2 days as washout periods. All experiments 
started at noon to minimize variation in baseline lung function and to 
avoid the "morning dip" that frequently occurs in patients with asth-
ma·'. 
The following measurements were determined each day: After a resting 
period of 30 minutes the patients exercised for 5 minutes on a bicycle 
ergometer at an individually fixed load that induced a heart rate of 
approximately 150 bpm after placebo. Heart rate and blood pressure 
were measured before, during the last minute of exercise, and 15 minu-
tes after exercise· At the same time lung function was assessed with 
flow-volume equipment. Several components of air flow rate were recor-
ded: FEVi and PEFR as parameters of large airways function, and MEF50 
and MEF25 mainly as parameters of smaller airways conductance^. 
These indices were obtained from the curve yielding the largest sum 
of FVC and FEVi5»19. Immediately after this first exercise test the 
medication was taken by mouth 30 minutes before a standard meal to a-
void differences in bioavailability within each individual^. Two 
hours after dosing a second exercise test was performed, which con-
sisted of 5 minutes bicycling at the same load as during the first 
exercise test. The same measurements were assessed before, during the 
last minute of exercise, and 15 minutes after exercise. Twenty-five 
minutes after this second exercise period (i.e., 2.5 hours after drug 
dosing) a dose-response curve was constructed by measuring the forced 
expiration indices, heart rate, and blood pressure 15 minutes after 
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terbutaline inhalation. Terbutaline was inhaled three times from a 
metered dose aerosol, each puff containing 0.5 mg terbutaline sulphate 
in cumulative doses of 0.5, 1 and 2 mg. 
Statistical analysis was performed by the Wilcoxon test for paired 
observations and correlations were calculated by the Pearson method2. 
Statistical significance was defined as p<0.05. 
RESULTS 
Study in healthy subjects. 
Both ^-blockers induced significant decreases in exercise-induced ta­
chycardia in comparison with placebo (p<0.01). The largest reduction 
in exercise-induced tachycardia was measured 2 hours after drug dos­
ing, at which time the effects of 400 mg bevantolol and 100 mg ateno­
lol were identical (-37 bpm) and greater than that of 200 mg bevanto­
lol (-34 bpm). The curves of the plasma concentrations of the 0-block-
ers are shown in Fig. 1. 
plasma concentration (ng/ml) 
2000 
1600 
1200 
Θ0Ο -i 
400 
t>--o bevantolol 2 0 0 mg 
•—· bevantolol 4 0 0 mg 
л—л atenolol IDO mg 
θ 
time ( h ) 
Fig. 1. Mean (+SE; n=6) plasma concentration after oral dosing with 
200 mg bevantolol, 400 mg bevantolol, and 100 mg atenolol. 
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The mean time of peak plasma concentrations was 1 hour 8 minutes for 
200 mg bevantolol, 1 hour 40 minutes for 400 mg bevantolol, and 2 
hours 40 minutes for 100 mg atenolol. The t^ for both doses of bevan-
tolol was approximately 2 hours, but the study period was too short 
to calculate a precise t^ for atenolol. There was a good correlation 
between plasma levels of the ß-blockers and the reduction In exercise-
Induced tachycardia (r"0.87 for bevantolol and r»0.84 for atenolol). 
Because 400 mg bevantolol could be regarded as cardloequlpotent to 100 
mg atenolol, the drugs were used In these doses to compare their ven-
tilatory effects In patients with asthma. 
Study in patients with asthma. 
There were no significant differences between the initial values of 
the indices measured on the different days of the study. At rest 2 
hours after drug dosing, mean (+SE) heart rate decreased by 10 + 2.4 
bpm after 400 mg bevantolol (p<0.01) and by 12.8 + 2.5 bpm after 100 
mg atenolol (p<0.01). Systolic blood pressure at rest decreased by 
9.5 + 3.2 mmHg after bevantolol (p<0.05) and by 12.3 + 2.3 mmHg 
after atenolol (p<0.01). There was no significant change in diastolic 
blood pressure during ^-blockade at rest. 
Results of the forced expiratory flow measurements are presented 
in Table II (next page) and Figs. 2 to 4 (page. 97, 98). Bevantolol 
400 mg, induced a decrease in FEV^ of 1.07 + 0.26 L and in PEFR of 
2.35 + 0.69 L/sec (p<0.01), whereas atenolol and placebo did not 
decrease these parameters (Table II). MEF50 and MEF25 fell signifi-
cantly after both ß-blockers, but the decline after bevantolol was 
significantly larger than that after atenolol. During exercise there 
was a significant increase (p<0.01) in the forced expiratory flow in-
dices measured during placebo, bevantolol, and atenolol dosing (Fig. 
2, upper panel). 
Fifteen minutes after the second exercise test during atenolol dos-
ing, FEVi significantly fell from 2.61 + 0.24 L before exercise to 
1.99 + 0.21 L after exercise, and PEFR declined from 6.45 + 0.56 to 
5.33 + 0.62 L/sec (Table II, Fig. 2, lower panel). Bevantolol signifi-
cantly decreased PEFR after exercise (from 4.63 + 0.58 to 4.28 + 0.60 
L/sec), whereas FEV^ did not change. During placebo there were no sig-
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TABLE II Ventilatory Indices before and after placebo, 400 mg bevantolol, and 100 mg atenolol, 
after exercise and after Inhalation of terbutallne 
FEV! (L) 
Placebo 
Bevantolol 400 
Atenolol 100 
PEFR (L/sec) 
Placebo 
Bevantolol 400 
Atenolol 100 
MEF50 (L/sec) 
Placebo 
Bevantolol 400 
Atenolol 100 
MEF25 (L/sec) 
Placebo 
Bevantolol 400 
Atenolol 100 
mg 
mg 
mg 
mg 
mg 
•g 
mg 
mg 
Initial values 
(5 min before 
dosing) 
2.91+0.31 
2.87+0.26 
2.79+0.26 
6.81+0.43 
6.98+0.56 
6.33+0.48 
2.16+0.42 
2.05+0.29 
1.98+0.35 
0.96+0.19 
0.96+0.15 
0.93+0.15 
2 hr after 
dosing 
2.83-Ю.Э0 
1.80+0.21 
2.61+0.24 
6.53+0.49 
4.6Э+0.58 
6.45+0.56 
1.93+0.38 
0.98+0.16 
1.60+0.26 
0.81+0.17 
0.45+0.06 
0.76+0.10 
Ρ 
value* 
NS 
<0.01 
NS 
NS 
<0.01 
NS 
NS 
<0.01 
«0.05 
NS 
«0.01 
«0.05 
2 hr 20 min 
after dosing 
(15 min after 
2nd exercise test) 
2.60+0.22 
1.70+0.22 
1.99+0.21 
6.33+0.45 
4.28+0.60 
5.33+0.62 
1.79+0.23 
0.99+0.16 
1.24+0.17 
0.80+0.08 
0.46+0.05 
0.60+0.07 
Ρ 
value+ 
NS 
NS 
«0.01 
NS 
«0.05 
«0.01 
NS 
NS 
NS 
NS 
NS 
NS 
After Inhalation 
of 2 mg 
terbutallne 
3.58+0.29 
2.58+0.31 
3.14+0.33 
8.31+0.51 
6.49+0.73 
8.00+0.80 
3.24+0.55 
1.79+0.28 
2.56+0.49 
1.56+0.28 
0.78+0.10 
1.15+0.21 
* + 
value+ 
«0.01 
«0.01 
«0.02 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
NS not significant. * Values 2 hr after dosing vs. Initial values. 
+
 Values 2 hr 20 min after dosing vs. values 2 hr after dosing. 
values 2 hr 20 min after dosing. 
+ Values after 2 mg terbutallne vs. 
during exercise 
FEV, (I) 
•ΟΘΟ 
MEF2 5(l/s) 
. 1 6 0 · 
15 mm after exercise 
Fig. 2. Mean (+SE;n=8) rise and fall in FEVi, MEF50 and MEF25 during 
and after the second exercise test 2 hours after drug dosing· 
Measurements were performed during the last minute of exercise 
(upper panel) and 15 minutes after exercise (lower panel) and 
differences were calculated from preexercise values 2 hours 
after drug dosing during placebo (P), 400 mg bevantolol (B), 
and 100 mg atenolol (A). NS - Not significant; *p<0.05; 
**p<0.01. 
ΔΡΕν,Ο) 
15 
10 
05 
220 240 
τ 
3 320 
time (h mm) 
Fig. 3. Mean (+SE,n-8) changes in FEV^ induced by inhalation of 
terbutaline in cumulative doses after placebo, 400 mg 
bevantolol, and 100 mg atenolol. 
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AMEFgod/s) 
2 0 
15 
10 
0 5 -
О -
о- -о placebo 
л—л atenolol 100 mg 
• ^ · bevantolol 4 0 0 mg 
Е2Э terbutalme 
(inhalation) 
2 20 2 4 0 3 3 2 0 
t ime (h min) 
15 
10 
0 5 
о- -о placebo 
- л—л atenolol 100 mg 
•—. bevantolol 400 mg 
ЕИЗ terbutalme (inhalation) 
K>--" 
2 20 240 3 320 
timeíh mm) 
Fig. 4. Mean (+SE;n-8) changes in MEF50 and MEF25 induced by inhala-
tion of terbutaline in cumulative doses after placebo, 400 mg 
bevantolol, and 100 mg atenolol. 
nlfleant changes in either FEVj or PEFR 15 minutes after exercise 
(Table II, Fig. 2, lower panel). There were no significant decreases 
in MEF50 and MEF25 after exercise as compared with preexercise va-
lues during placebo, bevantolol, and atenolol dosing. However, the 
decrease in MEF50 and MEF25 after exercise during atenolol dosing was 
significant as compared with the effect of bevantolol on these indices 
(Fig. 2, lower panel). The absolute values for FEV^, PEFR, MEF50 and 
MEF25 before and after the second exercise test, 2 hours and 2 hours 20 
minutes, respectively after bevantolol dosing, were significantly lower 
than the corresponding values during placebo and atenolol dosing 
(p<0.05; Table II). 
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Inhalation of terbutallne up to a cumulative dose of 2 mg signifi-
cantly increased the ventilatory indices measured (Table II; Figs. 3 
and 4). The bronchodilatory effect of terbutallne was smaller during 
bevantolol dosing than during placebo and atenolol dosing (Figs. 3 and 
4). During bevantolol dosing the absolute values of FEV^, PEFR, MEF50, 
and MEF25 after terbutallne inhalations were almost at the same level 
as the initial values before drug dosing, whereas during placebo and 
atenolol dosing the values after terbutallne were significantly higher 
than the initial values (Table II)· 
After the second exercise test all patients had at least one minor 
asthmatic attack. This happened seven times during bevantolol and only 
once after atenolol. All complaints disappeared immediately after the 
first inhalation of terbutallne and all patients left the clinical 
without complaints. 
DISCUSSION 
From our study in healthy subjects we conclude that 2 hours after drug 
dosing, 400 mg bevantolol was cardioequipotent to 100 mg atenolol, be-
cause at that time both ^-blockers induced equal decreases in exerci-
se-induced tachycardia. We therefore used both 3-blockers at these two 
doses to compare their effects on forced expiration parameters. The 
study was carried out in patients with asthma with »15% reversibility 
of the FEVi, because 0-blockers usually induce bronchospasm in such 
patients, while this effect is much smaller or absent in normal sub-
jects and in patients with low reversible or fixed bronchoconstric-
tion*'·1°»24. in the patients with asthma both ß-blockers induced the 
same reduction in heart rate at rest and during exercise, indicating 
the same degree of cardiac S-blockade. However, the two 0-blockers had 
significantly different effects on lung function. 
During bevantolol dosing there was a significant decrease in FEV^ 
and PEFR 2 hours after drug dosing before the second exercise test. A-
tenolol, however, did not induce such a decrease in these large air-
ways parameters at rest. Although both bevantolol and atenolol signi-
ficantly decreased MEF50 and MEF25, the reduction after bevantolol was 
99 
larger than that after atenolol. Small airways function at rest, 
therefore, seems to be more sensitive to 0-adrenoceptor blockade than 
large airway function in these patients with asthma. 
The normal rise in airway conductance during exercise, probably due 
to increased sympathetic tone^ · , was not influenced by either bevanto-
lol or atenolol; this is in accord with results of other studies"»^ . 
During atenolol dosing there was a significant decrease in FEVj^  and 
PEFR after exercise in comparison with the preexercise values 2 hours 
after drug dosing, while the differences in MEF50 and MEF25 between 
pre- and postexercise values were not significant. This increase in 
bronchoconstriction, especially In the larger airways, by exercise was 
not demonstrated during placebo dosing. During bevantolol dosing there 
was only a small decrease in PEFR after exercise, while FEV^ remained 
unchanged. The different effects of atenolol and bevantolol on bron-
chomotor tone after exercise are probably explained by the fact that 
bevantolol had already induced considerable bronchoconstriction before 
the second exercise test- Therefore, exercise-induced bronchoconstric-
tion can be enhanced by 0-adrenoceptor blockade, an effect that seems 
to depend on the preexercise bronchomotor tone. 
During therapy with 400 mg bevantolol the dose-response curves with 
terbutaline for FEVi, PEFR, MEF50 and MEF25 shifted downward In compa-
rison with placebo and atenolol, indicating less 0-adrenoceptor selec-
tivity for bevantolol at this dose than for atenolol.7»' 0-Adrenocep-
tor selectivity is, however, a dose-dependent phenomenon, >^ * and a 
smaller dose of bevantolol might show more 0x-adrenoceptor selectivi-
ty-
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SUMMARY 
1. Effects of single oral doses of atenolol 50 mg and xamoterol 200 mg 
(a recently developed partial Ö^-adrenoceptor agonist) on lung func-
tion, heart rate and blood pressure were investigated in 11 patients 
with asthma. 
2. The ß^-adrenoceptor selectivity of these drugs was assessed by com-
parison of dose-response curves of lung function parameters after in-
halation of the 02-adrenoceptor agonist terbutaline. 
3. Xamoterol caused a significant increase in heart rate and systolic 
blood pressure, indicating its partial P^-adrenoceptor agonist activi-
ty-
4. As xamoterol did not cause a bronchodilatation, it appears unlikely 
that there exists a βχ-adrenoceptor mediated bronchodilatation. 
5. Atenolol induced a significant increase in bronchoconstriction, 
while this occurred only in 3 patients during xamoterol. 
6. Atenolol SO mg and xamoterol 200 mg have a similar degree of 0}-
adrenoceptor selectivity-
Keywords: Asthma, atenolol, xamoterol, βχ-adrenoceptor function. 
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INTRODUCTION 
Soon after the introduction of nonselective ^-adrenoceptor antagonists 
it became clear, that these drugs can induce severe bronchospasm in 
asthmatic patients (McNeill, 1964). The introduction of B^-adrenocep-
tor selective antagonists seemed to be an advantage, but this type of 
S-blockers can also induce bronchoconstriction in asthmatic patients 
(Greefhorst and Van Herwaarden, 1981; Lammers et al, 1984; Ellis et 
al, 1981). The decline in lung function after a ß^-adrenoceptor-selec-
tive blocker can be explained via two possibilities: B^-adrenoceptor 
selectivity is a relative characteristic: increasing the dose leads to 
a decrease in selectivity (Fleming et al, 1978). Another possibility 
is that there are apart from $2~a^renocePt:ors also 0^-adrenoceptors in 
the airways by which bronchodilatation is mediated. In-vltro experi-
ments have demonstrated that the ratio of 02" t 0 Sj-adrenoceptors va-
ries between species (Rugg et al, 1978). Zaagsma et al (1983), how-
ever, could only demonstrate a homogeneous B2 - a^ r e n o c eP t o r population 
in human tracheal and bronchial smooth muscle. Results of experiments 
in asthmatic patients with prenalterol, a partial ß^-adrenoceptor ago-
nist, are conflicting. Lbfdahl and Svedmyr (1982) could not demonstra-
te a bronchodilator effect of prenalterol in asthmatics, whereas 
Greefhorst and Van Herwaarden (1983) on the contrary were able to de-
monstrate an increase in vital capacity after prenalterol in asthmatic 
patients. Xamoterol (ICI 118,587) was shown in animal experiments to 
exhibit a higher S^-adrenoceptor selectivity as prenalterol (Cook et 
al, 1984) and this compound has substantial partial @i-adrenoceptor 
agonist activity (Nuttall and Snow, 1982; Rousseau et al, 1983). It 
seems therefore of interest to investigate if the ß^-adrenoceptor ago-
nist activity of xamoterol has an effect on the lung function of asth-
matic patients. We also compared the ß^-adrenoceptor selectivity of 
xamoterol with the Bj^-adrenoceptor selectivity of a low dose of ateno-
lol in the same group of patients. 
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METHODS 
Eleven male patients with bronchial asthma (American Thoracic Society, 
1962) completed the study. Some clinical details are given In Table 1 
(next page). Their mean age was 36.6 years, their mean height 176.9 cm 
and their mean weight 73.7 kg. Five of them were cigarette smokers, 
the others being nonsmokers. There were 7 patients with atopic extrin-
sic asthma with one or more positive skin tests to inhalational al-
lergens. None of the patients suffered from cardiovascular diseases. 
Their ventilation was moderately to mildly disturbed: the forced expi-
ratory volume in one second (FEV^) ranged from 40 to 74% of the pre-
dicted normal value (Quanjer, 1983). In all patients FEV^ Increased 
15% or more after stimulation with a 82~ ad r e n o c eP t o r agonist. Broncho-
dilator medication was stopped at least 12 hours before the start of 
the first measurement on each study day. Cromoglycate and beclometha-
sone were not inhaled on the days of investigations. All patients re-
frained from smoking and drinking caffeine containing beverages 24 
hours before each study period. The study was approved by the local 
Ethics Committee and written informed consent was obtained from each 
patient before entry into the study. 
The investigations were performed on 3 different days. Placebo was 
given single-blind on the first day. On the 2 other days the patients 
received double-blind and in random order xamoterol 200 mg and ateno-
lol 50 mg. Between the study days 2 and 3 there was an interval of at 
least 4 days to serve as a washout period. All measurements started at 
noon to minimize the effects of diurnal rhythm in airway conductance 
which frequently occurs in asthmatics (Connolly, 1979). The study 
drugs were administered orally before a standard meal to avoid diffe-
rences in bioavailability within each subject (Melander et al, 1977). 
Before and 2 hours after drug intake the following measurements 
were performed after a resting period of at least 30 minutes: forced 
vital capacity (FVC), FEV^ and peak expiratory flow rate (PEFR) were 
derived from maximal expiratory flow-volume curves which were measured 
with a Fleisch nr 4 pneumotachograph. Heart rate (HR) was recorded 
with an electrocardiograph (Heilige) and blood pressure (BP) was 
assessed with the cuff-method (mean of 2 readings; Korotkoff phase 5). 
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TABLE 1 Patient characteristics 
Sub- Age Smoking Asthma Height Weight FEVi Therapy** 
ject (yrs) history type* (cm) (kg) actual Ζ Ζ 
(1) of predlc- Increase 
ted values with 
terbutaline 
55 
68 
74 
40 
57 
58 
47 
58 
70 
74 
57 
30 
25 
19 
29 
29 
18 
50 
35 
15 
24 
44 
-
В S 
-
S 
-
в s 
с s 
s 
s 
s 
s 
59.8+3.3 28.9+3.2 
* E - extrinsic; I • Intrinsic 
**B - beclomethasone; С - cromoglycate; S - salbutamol 
FEVi - forced expiratory volume In one second (1) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
mean 
58 
47 
32 
25 
24 
43 
38 
22 
60 
23 
31 
36.6+4.2 
+ 
-
-
-
+ 
+ 
-
-
+ 
-
+ 
1.50 
2.68 
3.40 
1.70 
2.60 
2.25 
1.70 
2.60 
2.28 
3.70 
2.50 
176.9+2.3 73.7+3.8 2.45-H).2 
I 
I 
I 
E 
E 
E 
E 
E 
I 
E 
E 
161 
182 
188 
171 
178 
178 
169 
180 
174 
185 
180 
68 
94 
74 
66 
61 
92 
54 
63 
80 
78 
81 
The values of the measurements obtained before drug Intake are refer-
red to as baseline values. Subsequently, dose-response curves with a 
02~adrenoceptor agonist were performed by assessing HR, BP and flow-
volume curves 15 minutes after inhalation of increasing doses of ter-
butaline. Terbutaline was administered with a metered dose Inhaler in 
cumulative doses of 0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg. In order to fa-
cilitate inhalation, terbutaline was inhaled through a Nebuhaler^ (As-
tra), being a cone-shaped extension device of 750 ml (Newman et al, 
1981). The results are presented as mean + SEM. For statistical ana-
lysis the Wilcoxon test for paired observations was used. Statistical 
significance was defined as p<0.05 (Colton, 1974). 
RESULTS 
No significant differences were found between the baseline values of 
the indices measured on the different days of the study. The effects 
of xamoterol and atenolol on the baseline values of HR and BP are 
shown in Figure 1 (upper panel). HR increased significantly by 10.8 + 
2.1 beats/min (p<0.01) 2 hours after intake of xamoterol and decreased 
significantly by 9.4 +1.5 beats/min (p^O.Ol) after atenolol. Xamote-
rol caused an increase in systolic BP of 7.4 + 2.0 mmHg (p<0.01), whe-
reas after atenolol systolic BP decreased by 8.3 + 1.5 mmHg (p<0.01). 
All three study drugs caused a significant fall in diastolic BP. The 
decline in diastolic BP after xamoterol and atenolol did not differ 
significantly from the effect of placebo on this parameter. 
The changes in lung function parameters 2 hours after drug Intake, 
as compared to the baseline values of the same day, are presented in 
Table 2 (page 111) and Figures 1 (lower panel) and 2 (page 109). Ate-
nolol caused a mean decrease in FVC of 0.35 1 and in FEVj of 0.35 1, 
both changes being significant. There was a tendency towards a decrea-
se in mean FVC and FEV} during xamoterol, but this mean change was, 
however, not significant. This effect of xamoterol on FVC and FEVj was 
caused by a decrease of more than 20% of baseline values in 3 of 11 
patients, as is shown for FEV^ in Figure 2. The mean PEFR did not 
change significantly which was mainly due to intra- and interindivi-
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dual variations of this parameter. The variability found in this stu­
dy, however, did not exceed the variability as described in the lite­
rature (Quanjer, 1983). 
Inhalation of terbutaline up to a cumulative dose of 4.0 mg had no 
effect on HR or systolic BP. Also diastolic BP did not change after 
terbutaline during placebo. However, diastolic BP did increase signi­
ficantly after 4.0 mg terbutaline during atenolol by 7.1 + 3.1 mmHg 
(p<0.02) and during xamoterol by 9.9 + 2.2 mmHg (p<0.01). 
The effects of terbutaline on lung function are shown in Table 2 
(next page) and Figure 3 (page 113). A significant improvement In FVC, 
FEVi and PEFR was found during placebo, atenolol and xamoterol. Compa­
rison of the increases in FVC and FEV^ by terbutaline did not reveal 
significant differences between placebo, atenolol or xamoterol (Fig. 
3). There was, however, a significant difference after maximal stimu­
lation with terbutaline between the absolute FEVi values of placebo 
and atenolol (p<0.02) and the FEV^ values of placebo and xamoterol 
(p<0.05), whereas there was no such significant difference between 
xamoterol and atenolol (Table 2). 
DISCUSSION 
The purpose of this study was to investigate the effects of xamoterol, 
a partial βχ-adrenoceptor agonist (Nuttall and Snow, 1982; Rousseau et 
al, 1983) on lung function, HR and BP in comparison with placebo and 
atenolol, a Bi-adrenoceptor-selective antagonist (Ellis et al, 1981; 
Lammers et al, 1985). The study was performed in asthmatic patients 
with a reversibility of their FEV^ of at least 15%, because these pa­
tients are more susceptible for the bronchoconstrictor effects of 8-
adrenoceptor antagonists as patients with a lower reversibility of 
their airways obstruction (Perks et al, 1978). 
As we were interested to see whether the intrinsic sympathomimetic 
activity of xamoterol has any effect on lung function, the patients 
were studied at rest, since it is shown that xamoterol acts as a Θ-
adrenoceptor agonist at low levels of sympathetic tone, but as a B-
adrenoceptor antagonist when sympathetic tone is high, as during exer-
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TABLE 2 Ventilatory parameters before and after intake of placebo, atenolol and xamoterol and 
after cumulative doses of terbutaline 
(mean + s.e.mean) 
FVC (1) 
placebo 
atenolol 
xamoterol 
FEV! (1) 
placebo 
atenolol 
xamoterol 
PEFR (l/s; 
placebo 
atenolol 
xamoterol 
50 
200 
50 
200 
)_ 
50 
200 
mg 
•8 
mg 
mg 
mg 
mg 
baseline 
values 
4.58+0.31 
4.58+0.29 
4.60+O.27 
2.89+0.27 
2.84+0.30 
2.95+0.24 
6.95+0.64 
7.36+0.72 
7.98+0.81 
values 2h 
after drug 
Intake 
4.56+0.28 
4.24+0.30 « 
4.35+0.32 
2.88+0.28 
2.49+0.28 « 
2.69+0.31 
7.13+0.72 
6.84+0.75 
6.83+0.73 
P* 
NS 
'0.02 
NS 
NS 
=0.01 
NS 
NS 
NS 
NS 
values after Inhalation of terbutaline 
0.5mg 
4.85+0.30 
4.66+0.28 
4.72+0.32 
3.17+0.32 
2.95+0.33 
3.04+0.36 
8.04+0.75 
7.97+0.89 
7.76+0.94 
P+ 
NS 
<0.01 
<0.01 
«0.05 
«0.01 
«0.01 
«0.02 
«0.05 
«0.05 
l.Omg 
5.01+O.30 
4.79+0.29 
4.84+0.32 
3.43+0.31 
3.12+0.34 
3.23+0.36 
8.52+0.78 
7.85+0.98 
8.42+1.00 
P+ 
«0.02 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
NS 
«0.01 
2.0mg 
5.05+0.27 
4.95+0.28 
5.31+0.31 
3.59+0.31 
3.33+0.34 
3.45+0.35 
9.01+0.76 
9.06+0.87 
8.99+0.90 
P+ 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
4.0iiig 
5.11+0.30 
5.0O+O.28 
5.05+O.32 
3.74+0.31 
3.37+0.34 
3.53+0.35 
9.37+0.91 
9.14+0.90 
9.14+0.88 
P+ 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
p*: values 2 h after drug Intake vs baseline values. 
p +: values after inhalation of terbutaline vs values 2 h after drug intake. 
NS: not significant. 
eise (Harry et al, 1981; Rousseau et al, 1983; O'Neill et al, 1984). 
HR and systolic BP were significantly decreased by atenolol 50 mg, 
while there was a significant increase in these parameters after xa-
moterol 200 mg (Figure 1). Xamoterol therefore has at rest an inotro-
pic effect, as shown by others previously (Rousseau et al, 1983; Löf-
dahl and Svedmyr, 1984). The effects of xamoterol and atenolol on 
diastolic blood pressure were probably mediated by rest, since diasto-
lic blood pressure also declined after placebo. Atenolol 50 mg induced 
a clear bronchoconstriction as can be concluded from the decrease in 
FVC and FEVi (Table 2 and Figure 1). In a previous study (Lammers et 
al, 1985) we did not find an effect of atenolol 100 mg on FEVx in 
asthmatic patients at rest. After exercise, however, there was a sig-
nificant fall in FEV]^ during atenolol 100 mg. It remains therefore un-
predictable how an asthmatic patient will react to even a low dose of 
a ß^-adrenoeeptor selective antagonist and the 0-adrenoceptor selecti-
vity of these drugs appears to be not completely dose-dependent as 
suggested by Ellis et al (1981) and Fleming et al (1978). 
Xamoterol induced an increase in HR and systolic BP, which effect 
is 0i-adrenoceptor mediated. On the contrary, xamoterol did not im-
prove lung function and it seems therefore unlikely that there exists 
a 0i-adrenoceptor mediated bronchodilatation. This appears to corre-
late well with radioligand binding studies in vitro, as Zaagsma et al 
(1983) could not demonstrate 3x-adrenoceptors in human bronchial 
smooth muscle. Conversely, it seems that bronchoconstriction induced 
by Βχ-adrenoceptor-selective blockers must be explained by a lack of 
selectivity of these drugs and not by a blockade of P^-adrenoceptors 
in the bronchial smooth muscles. 
Xamoterol caused a bronchoconstriction in 3 patients, as can be 
concluded from the fall in their FEV^ (Figure 2). Although these 3 pa­
tients had a reversibility of FEV^ of more than 25%, other patients 
with a high reversibility did not show a decrease in lung function af­
ter xamoterol. Löfdahl and Svedmyr (1984) also described a fall of 
more than 20% in 2 out of 8 asthmatic patients after an intravenous 
dose of xamoterol 0.1 mg/kg. 
The improvement in lung function after inhalation of terbutaline 
was similar for atenolol, xamoterol and placebo (Table 2, Figure 3). 
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Figure 3. Mean changes in FVC and FEV^ induced by terbutallne in cumu­
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placebo (·), xamoterol 200 mg (A) and atenolol 50 mg (о). 
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As dose-response curves with a B2~ a^ r e n o c eP t o r agonist during ß-
blockade are indicative for the ß-adrenoceptor selectivity of 
these drugs (Johnsson et al, 1975; Lammers et al, 1985), it can be 
concluded from Figure 3 that xamoterol 200 mg has similar ß^-adre-
noceptor selectivity as atenolol 50 mg. Nevertheless, both drugs 
should be used with care in asthmatic patients and only when conco-
mitantly ß-adrenoceptor agonists are administered. 
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SUMMARY 
In order to localize the main site of action of the ß2 - ad r e n o c eP t o r 
selective agonist terbutallne and the S^-adrenoceptor selective anta-
gonist atenolol In the airways of asthmatic patients, we compared the 
effects of these drugs on maximal expiratory flow-volume (MEFV) curves 
when breathing air and when breathing a helium-oxygen (Не-Оз) mixture. 
To investigate whether a shift in localization of the bronchodilator 
effect occurs when terbutallne is inhaled repeatedly, dose-response 
curves with terbutallne were performed for parameters derived from 
MEFV-curves when breathing air and for density dependence of expirato­
ry airflow. 
Atenolol caused constriction of large and small airways as measured 
with MEFV-curves when breathing air. Inhalation of terbutallne to a 
cumulative dose of 2.0 mg induced a stepwise improvement in expiratory 
airflow parameters for large and small airways function, when breath­
ing air. Doubling the dose to 4.0 mg did not result in any further im­
provement of lung function. Neither atenolol nor terbutallne did in­
duce significant mean changes in density dependence of expiratory air­
flow. This was partly due to large inter- and intraindividual varia­
tions of this parameter. Another possibility is that atenolol and ter­
butallne equally affected large and small airways function. 
INTRODUCTION 
Ventilatory effects of 0-adrenoceptor agonists and antagonists are 
usually assessed with routine lung function tests, such as measurement 
of total airway resistance, peak expiratory flow rate (PEFR), and the 
forced expiratory volume in one second (FEV^). Although these methods 
give insight in changes in overall lung function, they do not distin­
guish between the effects of these drugs on large or small airways· By 
measurement of airflow at high and low lung volumes, which can easily 
be performed with flow-volume curves, a distinction between the ef­
fects of drugs on large or small airways can be made (Mead et al, 
1967; Chick and Jenne, 1977; Pride, 1979). A further distinction be-
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tween the influence of drugs on large or small airways can probably 
be made by comparison of flow-volume curves, when the patient is 
breathing air and when he is breathing a low-density gas mixture like 
He-02 (Despas et al, 1972). 
This assessment of density dependence has been used to determine 
the site of bronchodilatation by S-adrenoceptor agonists and/or cho-
linergic antagonists (Ingram et al, 1977; Minette et al, 1985; Fairsh-
ter et al, 1981; Ashutosh et al, 1980). These studies concerned the 
bronchodilator effect of a single oral or inhaled dose of a bronchodi-
lator. We wondered if the consecutive administration of a 82-adreno-
ceptor agonist would induce a shift in the localization of the bron-
chodilator effect in asthmatic patients. 
As there is little information on the localization of the broncho-
constriction induced by 0-adrenoceptor antagonists in asthmatics, we 
investigated also the effect of atenolol, a 0i-adrenoceptor selective 
antagonist, on forced expiratory airflow parameters and density depen-
dence in the same group of asthmatic patients-
METHODS 
Eleven male patients aged 22 to 60 years, were studied. All suffered 
from asthma as defined by the American Thoracic Society (1962). Their 
mean height was 176.9 cm (range 161-188 cm) and their mean weight 73.7 
kg (range 54-94 kg). Five patients were smokers and 7 were allergic to 
one or more inhalational allergens. Their lung function was mildly to 
moderately disturbed: the FEV^ ranged from 40 to 74% of the predicted 
normal value (Quanjer, 1983). All patients had shown an increase in 
their FEVi of at least 15% after inhalation of a S2~adrenoceptor ago-
nist before they entered the study. They were in a stable phase of 
their disease and none of them required oral corticosteroids or theo-
phylline-derivatives. Eight patients used salbutamol by inhalation as 
bronchodilator medication; this was not used for at least 12 hours 
prior to the first measurement. Two patients inhaled beclomethasone 
dipropionate and 1 patient cromoglycate regularly; these drugs were 
not inhaled on the days of investigation. The study was approved by 
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the local Ethics Committee and written informed consent was obtained 
from each patient· 
Lung function parameters were obtained from maximal expiratory 
flow-volume (MEFV) curves, which were obtained with a flow-volume 
equipment containing a Fleisch No. 4 pneumotachograph. Before each set 
of measurements the flow-volume equipment (Discom, Chest Company To­
kyo) was calibrated separately with room air and a mixture of 80% 
helium and 20% oxygen (He-02)· Volume history was standardized by 
maximal inhalation to total lung capacity (TLC) prior to the perfor­
mance of all MEFV-curves. First, three MEFV-curves were obtained when 
breathing room air. Next, He-02 w a s washed in during 4 minutes when 
breathing this gas from a Douglas bag and thereafter a second set of 
three MEFV-curves was obtained. The air MEFV-curves with the best sum 
of forced vital capacity (FVC) and FEV^ (Gardner, 1977) were used for 
calculations of FVC, FEVj, PEFR and maximal expiratory flow rate when 
50% and 25% of the FVC still were to be expired (MEF50 and MEF25 res­
pectively). The He-02 MEFV-curves with the best fitting FVC's compared 
to the air MEFV-curves were used for calculation. We used as parameter 
for density dependence ЛМЕЕзд: 
AMEF = MEF
sn
(He-07) - MEFsn(alr) χ 1 0 0 % 
5 0
 MEF50(air) 
(Despas et al, 1972; Dosman et al, 1975). 
The volume of isoflow (V^
so
 γ) was calculated after superimposing the 
air and Не-Оз MEFV-curves at the level of residual volume (Hutcheon et 
al, 1974; Dosman et al, 1975). 
The investigations were performed on two different days. After 
assessment of baseline lung function at 12.00 AM study drugs were ad­
ministered by mouth. On the first day placebo was given single-blind 
and at the second occasion atenolol 50 mg, both as identical tablets. 
At 02.00 PM lung function measurements were repeated. Thereafter, a 
dose-response curve with the e2-adrenoceptor agonist terbutallne was 
performed by obtaining air and He-02 MEFV-curves 15 minutes after in­
halation. Terbutaline was inhaled four times through a 750 ml spacer 
(Nebuhaler^) from a metered dose inhaler (Newman et al, 1981) in cumu-
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Wllcoxon test for paired observations was used. Statistical signi­
ficance was defined as p<0.05. 
RESULTS 
Baseline values for the different lung functions measured are given 
in the table (page 123). No significant differences were found between 
these values between the two days of investigation. 
There were no changes in lung function parameters 2 hours after 
intake of placebo (Table). However, atenolol 50 mg caused a signifi­
cant fall in FVC, FEVi, MEF50 and MEF25. Density dependence and V l s o v 
were not influenced by atenolol. 
Inhalation of terbutaline caused a significant improvement in FVC, 
FEV^, PEFR, MEF50 and MEF25 (p<0.01), both during placebo and atenolol 
50 mg (Table). Dose-response curves with terbutaline for MEF50 and 
MEF25 are presented in Fig. 1 (next page). There was no significant 
difference between the dose-response curves during placebo and ateno­
lol for both parameters. 
The effects of consecutive inhalations of terbutaline on ДМЕГзд 
are shown in Figs. 2 and 3 (page 124). There was a tendency towards an 
increase in ДМЕРзо after inhalation of 0.5 mg terbutaline during pla­
cebo (Fig. 2). This difference was, however, not significant. As can 
be seen in Fig. 3, where the effects of terbutaline on ДМЕКзо during 
placebo treatment have been separated between smokers and nonsmokers, 
this small change in ДМЕРзо mainly occurred in the smoking patients. 
Further inhalation of terbutaline up to a cumulative dose of 4.0 mg 
did not influence ДМЕРзо, either during placebo or during atenolol 50 
mg. There also was no change in V£ s o у after inhalation of terbutaline 
(Table). 
DISCUSSION 
The effects of atenolol and terbutaline on the FEV^ and PEFR In this 
group of asthmatic patients have been described in detail in Chapter 7 
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Figure 1. Changes In MEF50 and MEF25 Induced by inhalation of 
terbutaline in cumulative doses as compared to values 
2 hours after intake of placebo (·) and atenolol 50 mg 
(о) (mean + SEM, n=ll). 
Since FEVi and PEFR are mainly determined by the resistance in the 
larger airways (Gelb and Klein, 1977; Pride, 1979), it appears that a-
tenolol caused a constriction and terbutaline a dilatation of the lar­
ger airways· Atenolol 50 mg also caused a constriction of smaller air­
ways as is indicated by the significant fall in MEF50 and MEF25 
(Pride, 1979; Minette et al, 1985; Chick and Jenne, 1977). 
Inhalation of terbutaline up to a cumulative dose of 2.0 mg result­
ed in a steady increase in MEF5Q and MEF25 during both placebo and 
atenolol (Fig. 1). Madsen et al (1983) suggested from the results of 
their study that for an effect on smaller airways of terbutaline a 
higher dose is required that for an effect on FEV^. We were not able 
to confirm their findings. After inhalation of 2 mg terbutaline a pla­
teau was reached for FEV^, MEF50 and MEF25 during both placebo and a-
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TABLE Ventilatory parametere before and 2 h after intake of placebo and atenolol 
and after inhalation of 4 mg terbutallne (mean+SEM, n-11). 
PLACEBO ATENOLOL 
FVC 
PEFR 
FEVx 
MEF50 
MEF25 
(1) 
d/e) 
(1) 
(l/e) 
d/e) 
ЛМЕРзо (Ζ) 
Viso V (ZFVC) 
baseline 
values 
4.58+0.31 
6.95+0.64 
2.8940.27 
2.1140.33 
0.8540.14 
38.745.0 
81.245.1 
2 h after 
drug intake 
4.5640.28 
7.1340.72 
2.8840.28 
2.1140.35 
0.8640.15 
31.148.2 
79.645.0 
Ρ* 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
after 4 mg 
terbutallne 
5.1140.30 
9.3740.91 
3.7440.31 
3.39+0.55 
1.3440.23 
38.345.5 
79.6+4.4 
P+ 
<0.01 
«0.01 
«0.01 
«0.01 
«0.01 
NS 
NS 
baseline 
values 
4.5840.29 
7.3640.72 
2.8440.30 
2.1040.35 
0.8640.16 
30.646.8 
81.145.2 
2 h after 
drug intake 
4.2440.30 
6.8440.75 
2.4940.28 
1.7040.29 
0.6640.12 
36.8+7.3 
76.0+4.3 
Ρ* 
«0.02 
NS 
«0.01 
«0.01 
«0.01 
NS 
NS 
after 4 mg 
terbutallne 
5.0040.28 
9.1440.90 
3.3740.34 
2.7540.53 
1.1140.22 
48.2+4.0 
81.6+2.9 
P+ 
«0.01 
«0.01 
«0.01 
«0.01 
«0.01 
NS 
NS 
P* - baseline values versus values 2 h after drug intake. 
P+ - values 2 h after drug intake versus values after terbutallne. 
NS - not significant. 
ДМЕРэдІЧ) 
50 
to 
30 
¿ 
-YS-
• placebo 
e atenolol 50 mg 
2h 
after 
drug 
intake 
1.0 2.0 10 І.0 tcrbutaline (mg) 
Figure 2. Effects of terbutallne in cumulative doses on ДМЕРзо 
during placebo (·) and atenolol 50 mg (о) (mean + SEM; n-11). 
Δ Μ Ε Ρ 5 0 { 4 ) 
Д fmoktr i ( η · 5 ) 
Δ non smokers ( η · 6 ) 
i.O Urbutolino (mg) 
Figure 3. Effects of terbutallne In cumulative doses on ЛМЕГзо 
during placebo In smokers (A) and non smokers (Δ) 
(mean + SEM). 
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tenolol, Indicating a simultaneous dilatation of large and small air­
ways by terbutaline. 
Despas et al (1972) introduced the measurement of density dependen­
ce as a method to assess the main localization of obstruction In the 
airways of patients with asthma and chronic bronchitis. A density de­
pendence of less than 20% indicates that the major site of obstruction 
is located in small peripheral airways, while a density dependence of 
more than 20% is compatible with mainly large airways obstruction 
(Despas et al, 1972; Dosman et al, 1975). 
Later on, Hutcheon and coworkers (1974) and Dosman et al (1975) 
described the volume of isoflow as another method to discriminate 
between large and small airways function. 
A volume of isoflow, at which the MEFV-curves when breathing air 
and when breathing He-02 coincide, of more than 80% is assumed to de­
monstrate that the major site of bronchoconstrlctlon is located in 
larger airways. Both parameters have been used to assess the main 
site of action of bronchoconstrictor and bronchodilator agents. Seve­
ral authors (Minette et al, 1985; Ashutosh et al, 1980; Hensley et 
al, 1978; Ingram et al, 1977; Chick and Jenne, 1977; Fairshter et 
al, 1981) mentioned a different localization of the bronchodilator 
effects of cholinergic antagonists and 8-adrenoceptor agonists. While 
the former mainly give dilatation of larger airways, the latter would 
preferentially dilate smaller airways. 
In our patients the 0^-adrenoceptor selective antagonist atenolol 
did not affect mean density dependence or the mean value of the volume 
of isoflow. By this method, therefore, no distinction could be made 
between the effects of atenolol on large or small airways. 
During placebo, there was no significant change in density depen­
dence or the volume of isoflow after inhalation of terbutaline. There 
was, however, a tendency towards a mean increase in density dependence 
after inhalation of 0.5 mg terbutaline in smoking patients (Fig. 3). 
This small rise in ДМЕГзд was followed by a decrease after further 
inhalation of terbutaline. From these results it seemed that broncho-
dilatation by terbutaline first occurred in the smaller airways of 
these smoking asthmatics and after a higher dose shifted to larger 
airways. These changes were, however, not significant and the small 
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number of smoking patients (5) prohibits too many conclusions. More­
over, at every point in the dose-response curves of ДМЕРзо of all pa­
tients, there were large intraindividual and interindividual variati­
ons resulting in mean values with high standard errors. Other authors 
(Bonsignore et al, 1980; Mc Donald and Cole, 1980; Berend et al, 
1981) also described a large variability of density dependence and 
vlso V* Recently, It has been suggested that sites of flow limita­
tion, airway geometry and patterns of flow may differ with the density 
of the respired gas (Mink and Wood, 1980; Knudson and Schröter, 1983), 
and it therefore remains questionable whether this method is reliable 
enough to localize bronchodilatation and bronchoconstriction. 
On the other hand, it is possible that asthmatic patients do not 
have a uniform pattern in their reactions to bronchoconstrlctor and 
bronchodilator stimuli. 
Another possibility might be that atenolol and terbutaline causes 
proportionately equal constriction and dilatation of large and small 
airways, leaving density dependence relatively unchanged (Ingram et 
al, 1977). 
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CHAPTER 9 
SUMMARY AND CONCLUSIONS 
SUMMARY 
The main components of the autonomic nervous system of the lung and 
airways are the parasympathetic or cholinergic system and the sympa­
thetic or adrenergic system. The latter can be subdivided into the a-
adrenergic and the B-adrenergic system. An imbalance between the ex­
citatory cholinergic and the α-adrenergic system on the one hand and 
the inhibitory 0-adrenergic system on the other hand Is supposed to be 
an important factor in the pathogenesis of asthma. 
In the studies presented in this thesis we approached the function 
of the pulmonary 0-adrenergic system in patients with chronic nonspe­
cific lung disease (CNSLD) from a clinical-pharmacological point of 
view. In this respect we studied the effects of 0-adrenoceptor block­
ade and stimulation on the lung function of patients with asthma and 
chronic obstructive bronchitis. 
Chapter 1 presents a general Introduction with an outline of the stud­
ies reported in this thesis. 
In Chapter 2 we describe some aspects of the autonomic regulation of 
the lung and airways. There is ample evidence that cholinergic effe­
rent nerves which travel through the vagal nerves, innervate bronchial 
smooth muscles and mediate bronchoconstriction. In normal subjects 
there is some vagal bronchomotor tone, but in patients with asthma 
the cholinergic influence is much more pronounced. In contrast to a 
rich cholinergic nerve supply, the adrenergic innervation of the human 
lung is sparse. The bronchoconstrictor and bronchodilator action of 0-
adrenoceptor antagonists and agonists respectively, in asthmatic pa­
tients has to be explained by interaction with 0-adrenoceptors on the 
airway smooth muscles. The presence of a high density of these 0-adre-
noceptors has been documented by radioligand binding studies and re­
cently by means of autoradiography. The 0-adrenoceptors can functio­
nally be divided into β γ- and 02-subtypes. From the results of in-
vitro experiments it appears that the human bronchial smooth muscles 
contain a homogeneous population of 02-adrenoceptors. Nonselective 0-
blockers antagonize both 0^- and 02-adrenoceptore. Since blockade of 
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^"adrenoceptors in airway smooth muscles of asthmatic patients re­
sults in bronchoconstriction, nonselective B-adrenoceptor antagonists 
can cause bronchospasm in these patients by blockade of 02 - a^ r e n o c eP~ 
tors in the airway smooth muscles. However, B^-adrenoceptor-selective 
blocking agents can also induce some bronchoconstriction, especially 
in larger doses. It has been suggested that the B-adrenergic system 
may modulate vagal bronchomotor tone by interference at the level of 
the cholinergic ganglia in the airway wall. Blockade of 0 2 ~ а ^ г е п о с е Р -
tors and possibly also of B^-adrenoceptors at this location may en­
hance cholinergic-mediated bronchoconstriction. This theory, however, 
is still unproven and a more probable explanation of the bronchocon­
striction caused by Bi-adrenoceptor selective blockers seems to be a 
lack of selectivity of these compounds. 
A third nervous system in the lung, the so-called nonadrenergic, 
noncholinergic system, has also been described, but the function of 
this inhibitory system is not yet well defined. 
In Chapter 3 we review several methods to assess the effects of B-
adrenoceptor agonists and antagonists on dynamic lung function in pa­
tients with CNSLD. Functionally, the airway system can be divided into 
large and central airways on the one hand, and small or peripheral 
airways on the other. Total airway resistance and peak expiratory flow 
rate (PEFR) are parameters which mainly give information on the func­
tion of the larger airways. The forced expiratory volume in one second 
(FEVi) is also largely determined by the calibre of the larger air­
ways, although changes in smaller airways can influence FEV^ to some 
extent. Frequency dependence of lung compliance and closing volume are 
parameters which are sensitive to changes In small airways, but only 
when other lung function tests are normal. Maximal expiratory flow-
volume (MEFV) curves, on the other hand, seem to provide an easily 
performed method to determine large and small airways function at the 
same time, also when routine lung function tests such as FEV^ are ab­
normal. Especially the assessment of density dependence, being the 
difference between MEFV-curves when breathing air and those when 
breathing a low-density gas mixture (80% helium and 20% oxygen), has 
gained interest for the localization of the effects of drugs In the 
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airways. The substantial variability of this method, however, is a 
disadvantage. 
Comparative studies of the bronchoconstrictor effects of different 
^-adrenoceptor blockers and their interaction with the bronchodilator 
action of a 02 - ad r e n o c eP t o r agonist in patients with asthma have prov-
ed to be a good model to assess the Bi-adrenoceptor selectivity of 0-
blockers in man. 
In Chapter 4 we describe a double-blind, placebo-controlled study of 
the bronchoconstrictor effects and di-adrenoceptor selectivity of me-
toprolol, a well-known 0^-selective blocker, and bisoprolol, a recent-
ly developed 3-adrenoceptor antagonist in asthmatic patients. Because 
100 mg metoprolol appears to be cardioequipotent to 10 mg bisoprolol, 
these doses were compared. Also 20 mg bisoprolol was studied to see 
whether the ß^-adrenoceptor selectivity of this drug was diminished at 
a higher dosage. Both ß-blockers caused bronchoconstriction as indi-
cated by a significant fall in PEFR. Decreases in vital capacity (VC) 
and FEV^ were significant only during 10 mg bisoprolol. Inhalation of 
the 02-a^r'enocePtor agonist terbutaline induced immediate bronchodila-
tation both during placebo treatment and during the three ß-blocker 
doses. There was no difference in the shape and position of the terbu-
taline dose-response curves of FEVj and PEFR during placebo or any of 
the 0-blockers. Both ß-blockers caused equally significant decreases 
in heart rate (HR), and 20 mg bisoprolol and 100 mg metoprolol also 
caused a significant fall in systolic and diastolic blood pressure 
(BP). Inhalation of terbutaline to a cumulative dose of 3.5 mg had no 
effect on HR and BP. These results indicate good 0^-adrenoceptor se-
lectivity of 100 mg metoprolol and 10 mg and 20 mg bisoprolol. 
Ventilatory effects of ^-blockers in patients with CNSLD are usually 
assessed in single-dose studies. 
In Chapter 5 we describe a comparative double-blind, cross-over study 
of the effects of long-term treatment with the B^-adrenoceptor-selec-
tive antagonist metoprolol and the nonselective (З-Ыоскег with intrin­
sic sympathomimetic activity (ISA) pindolol in patients with CNSLD 
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and concomitant hypertension. Bronchodilator therapy was continued 
throughout the study period. There were no changes in daily measured 
PEFR or pulmonary complaints during treatment with both ß-blockers. 
There was a small, but significant decrease in FEV^ during metoprolol, 
but not during pindolol. This difference can probably be explained by 
the effect of the ISA of pindolol on the ß2-adrenoceptors In the air-
ways. The ß2~ a^ r e n o c eP t o r agonist terbutallne induced significant 
bronchodilatation during placebo and metoprolol but not during pindo-
lol treatment. This disparity can be explained by the nonselective 
character of pindolol. There were no changes in the parameters of 
small airways function in this group of patients, either during place-
bo or during treatment with one of the 0-blockers. Moreover, terbuta-
llne did not influence the small airways parameters, which may be due 
to structural changes in the smaller airways of these patients. We 
concluded from this study that, if a ß-adrenoceptor blocker is neces-
sary in patients with CNSLD, a 0^-adrenoceptor-selective blocker is to 
be preferred in combination with bronchodilator agents such as 02" 
adrenoceptor agonists, and under regular monitoring of lung function. 
Chapter 6 discusses the effects of ß-adrenoceptor blockade at rest and 
during and after exercise on large and small airways function. For 
this purpose the effects of the ß^-adrenoceptor-selective blocker ate-
nolol on dynamic lung function parameters were compared with those of 
a cardioequipotent dose of a new ß-blocker, bevantolol, in asthmatic 
patients with reversible airways obstruction. The Interaction of both 
ß-blockers with the 02-agonist terbutallne was also studied. At rest, 
bevantolol caused generalized bronchoconstriction, whereas atenolol 
induced only some obstruction of smaller airways. However, after exer-
cise atenolol also caused large airways obstruction. The bronchodila-
tor effect of terbutallne was similar during placebo and atenolol 
treatment but was attenuated during bevantolol. It was therefore con-
cluded that atenolol is more ß^-adrenoceptor-selective than bevantolol 
in the doses used in this study. However, exercise can enhance the ef-
fects of ß^-adrenoceptor selective antagonists on lung function and 
therefore these ß^-selective blockers should be used with care, or not 
at all, in patients with readily reversible airways obstruction. The 
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normal rise in airway conductance during exercise was not attenuated 
by 3-adrenoceptor blockade. It therefore seems doubtful whether this 
rise in expiratory airflow parameters is caused by a higher level of 
sympathetic tone during exercise, as often suggested. 
Chapter 7 discusses the question whether there exists a 0^-adrenocep-
tor mediated bronchodilatation and/or bronchoconstriction. For this 
purpose we studied the ventilatory effects of xamoterol, a recently 
developed partial @i-adrenoceptor agonist, on lung function in 11 
asthmatic patients at rest. To assess the S^-adrenoceptor selectivity 
of this compound we compared dose-response curves of dynamic lung 
function parameters upon inhalation of terbutaline during xamoterol, 
placebo and the ß^-adrenoceptor-selective antagonist atenolol. After 
200 mg xamoterol 3 patients showed a decrease in FEV^, while atenolol 
caused more pronounced bronchoconstriction. Several patients who did 
not show a decrease in FEV| after 100 mg atenolol during a previous 
study showed an increase in bronchoconstriction after 50 mg atenolol 
in the present study. The question therefore remains whether 0^-adre-
noceptor selectivity is really a dose-dependent phenomenon. Other fac-
tors such as hyperreactivity of the airways, may also influence the 
effect of a 0i-adrenoceptor-selective blocker on the airways of asth-
matic patients. 
Dose-response curves with terbutaline were assessed by inhalation 
of cumulative doses through a 750 ml spacer (Nebuhaler^, Astra), 
which proved to be an effective method. Xamoterol (200 mg) showed the 
same 0^-adrenoceptor selectivity as 50 mg atenolol. Since xamoterol 
did not induce bronchodilatation, it appears unlikely that there 
exists 0i-adrenoceptor-mediated bronchodilatation. 
It has been suggested In the literature that the bronchodilator and 
bronchoconstrictor effects of drugs can be differentiated as to a more 
central or a more peripheral action in the airways. In order to loca-
lize the main site of action of the 02 - a^ r e n o c eP t o r - s e^ e c t^ v e agonist 
terbutaline and the ß^-adrenoceptor-selective antagonist atenolol in 
the airways of asthmatic patients, we compared the effects of these 
drugs on maximal expiratory flow-volume (MEFV) curves when breathing 
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air and when breathing a helium-oxygen mixture (Chapter 8)· Atenolol 
and terbutaline caused constriction and dilatation of large and small 
airways, respectively, as measured with MEFV-curves when breathing 
air. Neither atenolol nor terbutaline induced significant mean changes 
in density dependence (ДМЕРзо) of expiratory airflow. We found large 
intra- and interindividual variations in this parameters, which may 
cast some doubt on the usefulness of this method to localize the major 
site of action of drugs in the airways. On the other hand, it is pos­
sible that asthmatic patients do not have a uniform pattern in their 
reactions to bronchoconstrictor and bronchodilator stimuli. Another 
possibility is that atenolol and terbutaline equally affected the 
functions of large and small airways, leaving density dependence rela­
tively unchanged. 
CONCLUSIONS 
1. The 0|-adrenoceptor selectivity of 0-blockers is a relative charac­
teristic. 
2. B^-Adrenoceptor stimulation by exogeneously administered S^-adre-
noceptor agonists does not cause bronchodilatation. 
3. The increase in forced expiratory airflow during exercise is not 
caused by an increase in sympathetic tone. 
4. A clear separation between the effects of 92-a<ärenocePtor_8e^ect:'-ve 
stimulation on the function of large or small airways in asthmatic pa-
tients could not be assessed. 
5. If a ß-adrenoceptor blocking agent is required in patients with 
CNSLD, a 8i-adrenoceptor selective blocker is to be preferred with 
concomitant use of 02-a<^renocePt:or agonists and under regular monitor-
ing of lung function· 
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SAMENVATTING EN CONCLUSIES 
SAMENVATTING 
Astma, chronisch obstructieve bronchitis en emfyseem behoren tot een 
groep longziekten, welke meestal aangeduid wordt als chronisch aspe-
cifieke respiratoire aandoeningen (CARA). Deze algemene term is geïn-
troduceerd, omdat genoemde ziektebeelden vaak beschouwd worden als 
verschillende uitingsvormen van één syndroom, waarbij gemeenschappe-
lijke oorzaken een rol spelen. Bovendien kunnen bij CARA-patiënten de 
ziekteverschijnselen in de tijd variëren, en de verschillende ziekte-
beelden zijn vaak moeilijk of niet van elkaar te onderscheiden. 
In Hoofdstuk 1 is aangeduid, dat meerdere factoren tot CARA kunnen 
leiden. Een stoornis in de regulatie van de functie van longen en 
luchtwegen door het autonome zenuwstelsel wordt vaak als één van 
deze factoren genoemd. 
Hoofdstuk 2 beschrijft een aantal aspecten van de autonome regulatie 
van longen en luchtwegen. De belangrijkste componenten hiervan zijn 
het parasympathische of cholinerge systeem en het sympathische of 
adrenerge systeem. Er zijn voldoende aanwijzingen, dat cholinerge 
zenuwvezels vanuit het centrale zenuwstelsel en lopende via de ner-
vus vagus, de gladde spieren van de luchtwegen innerveren. Bij ge-
zonde personen lijkt er altijd enige tonus (spanning) in deze bron-
chiale gladde spieren aantoonbaar te zijn, wat door cholinerge activi-
teit veroorzaakt wordt. Bij astmapatiënten is dit echter meer uitge-
sproken. De menselijke long heeft een rijke cholinerge zenuwvoorzie-
ning, maar slechts een spaarzame adrenerge innervatie. De luchtweg-
vernauwende en -verwijdende effecten van respectievelijk B-adrenocep-
tor blokkerende en stimulerende geneesmiddelen bij astmapatiënten kun-
nen verklaard worden door koppeling met zogenaamde ß-adrenoceptoren, 
die op de gladde spiercellen van de luchtwegen aanwezig zijn. De aan-
wezigheid van een groot aantal van deze 0-adrenoceptoren is aangetoond 
met behulp van zogenaamde radioligand binding studies en recentelijk 
door middel van autoradiografie. De 3-adrenoceptoren kunnen functio-
neel ingedeeld worden in twee subtypen: de 3^- en de 02-a(irenocepto-
ren. Uit radioligand binding studies blijkt dat de gladde spiercellen 
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van menselijke luchtwegen alleen het 02-subtype bevatten. Blokkade van 
deze ß2-a(ärenoceptoren leidt tot luchtpijpvernauwing (bronchoconstric-
tie) bij astmapatiënten. 0-Adrenoceptor blokkerende geneesmiddelen 
worden veelvuldig gebruikt bij hart- en vaatziekten, zoals hypertensie 
en angina pectoris. De niet-selectieve B-blokkers blokkeren zowel Bi-
ais 32-adrenoceptoren en kunnen dus bij astmapatiënten bronchocon-
strictie veroorzaken. 3i-Adrenoceptor selectieve blokkeerders blokke-
ren voornamelijk de ß^-adrenoceptoren. Dit type 0-blokker blijkt ech-
ter ook bronchoconstrictie te kunnen veroorzaken, zij het meestal pas 
in hogere doseringen. De meest waarschijnlijke verklaring hiervoor 
lijkt te zijn, dat de B^-adrenoceptor selectiviteit een relatieve ei-
genschap is. Bij ophogen van de dosis gaat de Βχ-adrenoceptor selec­
tiviteit gedeeltelijk verloren en worden er ook B2~adrenoceptoren ge­
blokkeerd. Anderzijds wordt er wel gesuggereerd dat het B-adrenerge 
systeem in de long een remmende invloed uitoefent op het bronchocon-
strictief werkende cholinerge systeem. Stimulatie van B^- en/of 82" 
adrenoceptoren, gelegen in of op de cholinergia ganglia in de bron-
chuswand, zou een vermindering geven van de cholinerge zenuwprikkel-
geleiding. Blokkade van deze B-adrenoceptoren door B-blokkers daaren­
tegen zou de cholinerge bronchoconstrictie kunnen versterken. Voorals­
nog zijn er echter onvoldoende gegevens om deze laatste hypothese te 
bewijzen. 
In Hoofdstuk 3 worden enige methoden beschreven om de effecten van 0-
adrenerge blokkerende en stimulerende geneesmiddelen op de longfunctie 
te meten. Functioneel gezien kan het luchtwegsysteem onderverdeeld 
worden in centrale of grotere luchtwegen enerzijds en perifere of 
kleinere luchtwegen anderzijds. Er worden een aantal longfunctietesten 
beschreven, waarvan er enige voornamelijk de functie van de grotere 
luchtwegen weergeven en andere meer gevoelig zijn voor veranderingen 
in de kleinere luchtwegen. Ook worden methoden beschreven waarmee ge­
lijktijdig de functie van grotere en kleinere luchtwegen bepaald kan 
worden. 
Middels de studies in dit proefschrift hebben wij de functie van het 
B-adrenerge systeem bij CARA-patiënten benaderd vanuit een klinisch-
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farmacologisch gezichtspunt. Daartoe werden de effecten onderzocht van 
0-adrenoceptor blokkade en stimulatie op de longfunctie van patiënten 
met astma en chronisch obstructieve bronchitis. 
Vergelijkend onderzoek naar de effecten van verschillende ß-blokkers 
op de longfunctie van astmapatiënten geeft, vooral wanneer dit gecom-
bineerd wordt met toediening van 02 - a <l r e n o c eP t o r stimulerende midde-
len, inzicht in de mate van ß^-adrenoceptor selectiviteit van deze 0-
blokkers. 
In Hoofdstuk 4 wordt een dergelijk onderzoek beschreven naar de 0^-
adrenoceptor selectiviteit van de al langer bekende 0^-adrenoceptor 
selectieve blokker metoprolol en de recentelijk ontwikkelde 0-blokker 
bisoprolol. De 0-blokkers veroorzaken enige bronchoconstrictie, welke 
snel opgeheven kan worden door inhalatie van de 02-adrenoceptor stimu-
leerder terbutaline. Belde 0-blokkers bezitten derhalve een goede mate 
van 0^-adrenoceptor selectiviteit in de onderzochte doseringen. 
Effecten van 0-blokkers op de luchtwegen van patiënten met CARA 
worden meestal bestudeerd na een eenmalige toediening van een 0-blok-
ker. Voor de dagelijkse praktijk is langduriger gebruik echter min-
stens zo belangrijk, mede gezien het feit dat er in de literatuur 
gesuggereerd wordt, dat de negatieve invloed van deze geneesmidde-
len op de longfunctie kan toenemen bij regelmatig gebruik. 
In Hoofdstuk 5 worden de resultaten besproken van een vergelijkend on-
derzoek naar de effecten van de 0-blokkers metoprolol en pindolol op 
de longfunctie van CARA-patiënten, nadat beide middelen gedurende een 
maand gebruikt zijn. Tijdens de studieperiode worden bronchusverwij-
dende geneesmiddelen vrijwel onveranderd gecontinueerd. De pulmonale 
klachten van de patiënten blijken niet nadelig beïnvloed te worden 
door behandeling met de onderzochte 0-blokkers. Wel worden er bij 
longfunctiemeting kleine verschillen tussen beide 0-blokkers ge-
constateerd, die toegeschreven worden aan verschillende eigenschappen 
van de twee onderzochte 0-blokkers. De resultaten van dit onderzoek 
wijzen erop, dat in uitzonderlijke gevallen 0-blokkerende behandeling 
mogelijk is bij patiënten met CARA. De voorkeur gaat dan uit naar een 
01-adrenoceptor selectief middel met gelijktijdig gebruik van bron-
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chusverwijdende geneesmiddelen. Bovendien is regelmatige longfunctie-
controle aangewezen. 
Hoofdstuk 6 beschrijft een onderzoek naar de effecten van 0-adrenocep-
tor blokkade en stimulatie op grotere en kleinere luchtwegen van pa-
tiënten met astma. Tevens wordt het gecombineerde effect van 0-adreno-
ceptor blokkade en inspanning onderzocht. In rust veroorzaakt de 0^-
adrenoceptor selectieve blokker atenolol alleen constrictie van klei-
nere luchtwegen· Na inspanning veroorzaakt atenolol echter een alge-
hele bronchoconstrictle. De nieuwe 0-blokker bevantolol veroorzaakt in 
rust al een constrictie van grotere en kleinere luchtwegen, welk ef-
fect niet versterkt wordt door inspanning. In de in dit onderzoek 
gebruikte doseringen lijkt atenolol een hogere 0^-adrenoceptor selec-
tiviteit te bezitten dan bevantolol. Normaliter treedt er tijdens in-
spanning een toename op van de geforceerde uitgeademde luchtstroom 
(expiratoire flow). ^-Adrenoceptor blokkade verhindert deze stijging 
in expiratoire flow niet. Dit fenomeen lijkt derhalve niet, zoals aan-
genomen wordt, veroorzaakt te worden door een hogere activiteit van 
het B-adrenerge systeem tijdens inspanning. 
Zoals beschreven, wordt het bronchoconstrlctieve effect van een Sj-
adrenoceptor selectieve blokker enerzijds toegeschreven aan een gebrek 
aan 0j-adrenoceptor selectiviteit van deze middelen, anderzijds be-
staat de mogelijkheid dat blokkade van B^-adrenoceptoren in de lucht-
wegen tot bronchoconstrictle leidt. Om de eventuele functie van (З^ -
adrenoceptoren in de luchtwegen nader te evalueren, hebben wij de in­
vloed onderzocht van een 3^-adrenoceptor stimulerend middel, xamote-
rol, op de longfunctie van astmapatiënten (Hoofdstuk 7). Uit de resul-
taten van dit onderzoek blijkt, dat 02~adrenoceptor stimulatie wel 
bronchusverwijding veroorzaakt, maar dat 0^-adrenoceptor stimulatie 
door middel van xamoterol geen bronchusverwijding tot gevolg heeft. 
Een lage dosis van de 0^-adrenoceptor blokker atenolol daarentegen 
veroorzaakt in dezelfde patiëntengroep een duidelijke bronchoconstric-
tle. Dit wordt waarschijnlijk veroorzaakt door blokkade van 02-adreno-
ceptoren door atenolol, daar selectiviteit een relatieve eigenschap 
is. De vraag of zuivere ß^-adrenoceptor blokkade wel of niet tot bron-
choconstrictle aanleiding kan geven, is vooralsnog onbeantwoord. 
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Hoofstuk 8 beschrijft een studie naar de effecten van de 0^-adreno-
ceptor selectieve blokkeerder atenolol en de 02 _ a^ r e n o c eP t o r selec-
tieve stimuleerder terbutallne op de grotere en kleinere luchtwegen 
van astmapatlënten. Geen van beide middelen blijkt een duidelijke 
voorkeur te hebben voor grotere of kleinere luchtwegen. Atenolol ver-
oorzaakt een gegeneraliseerde bronchusvernauwlng en terbutallne een 
gegeneraliseeerde bronchusverwijding. Gezien de variabiliteit van de 
resultaten van één van de gebruikte meetmethoden, is het discutabel of 
deze methode wel geschikt is voor het onderscheiden van de effecten 
van geneesmiddelen op grotere of kleinere luchtwegen. 
CONCLUSIES 
1. De S^-adrenoceptor selectiviteit van 0-blokkers is een relatieve 
eigenschap. 
2. 3i_Adrenoceptor stimulatie middels exogeen toegediende 0j-adreno-
ceptor agonlsten leidt niet tot bronchodilatatie. 
3. De stijging van de geforceerde expiratoire luchtstroom tijdens in-
spanning wordt niet veroorzaakt door een verhoogde sympathicotonus. 
4. Er is geen duidelijke schelding mogelijk van de effecten van 0-
adrenoceptor selectieve stimulatie op de functie van enerzijds de 
grotere en anderzijds de kleinere luchtwegen van astmapatiënten. 
5. Wanneer behandeling van CARA-patiënten met een 0-blokker noodzake-
lijk is, dan dient een 0^-adrenoceptor selectieve blokker voorge-
schreven te worden in combinatie met een 02-adrenoceptor agonist. 
Regelmatige longfunctie-controle is dan eveneens vereist. 
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STELLINGEN 
behorend bij het proefschrift 
Beta-adreaoceptor blockade and stimulation 
In obstructive lung disease 
J-W.J. LAMMERS 
I 
Bronchodllatatle tijdens Inspanning wordt niet veroorzaakt door een 
verhoogde activiteit van het sympathische zenuwstelsel. 
(Dit proefschrift) 
II 
Betaj^-adrenoceptor stimulatie veroorzaakt geen bronchodllatatle. 
(Dit proefschrift) 
III 
In het zeldzame geval dat aan CARA-patiënten een beta-blokker voorge-
schreven dient te worden, biedt een beta-blokker met intrinsieke sym-
pathicomimetische activiteit geen voordelen boven een beta-blokker 
zonder deze eigenschap. 
(Dit proefschrift) 
IV 
Bronchiale hyperreactiviteit kan aangetoond worden door middel van in-
halatieprovocatietesten of inspannlngsonderzoek. Registratie van de 
flow-volume curve verdient hierbij de voorkeur boven het gebruik van 
de Wright peak-flow meter. 
V 
Een obstructieve longfunctiestoornis Is slechts dan irreversibel te 
noemen, wanneer met intensieve bronchodilaterende behandeling, waaron-
der systemische toediening van corticosteroïden, geen verbetering van 
de longfunctie bereikt kan worden. 
VI 
Bij de symptomatische behandeling van het centraal gelocaliseerde ob-
struerende bronchuscarclnoom dienen lasercoagulatle en/of het plaatsen 
van een endobronchiale buisprothese tenminste overwogen te worden. 
(J. Feeten et al. Ned Tijdsch Geneesk 128: 214-217, 1984) 
(Eigen ervaring) 
VII 
Ook incidenteel gebruik van nasale insufflatie-corticosteroïden kan 
effectief zijn bij allergische rhinitis. 
(Eigen waarneming) 
VIII 
Indien het nicotineverbruik door vrouwen niet snel afneemt, zal de 
langere levensverwachting van deze sekse in rook opgaan. 
IX 
Anorectale spasme bij proctalgia fugax kan opgeheven worden door Inha-
latie van een beta2-adrenoceptor agonist. 
(J.E. Wright, Lancet II: 659-660, 1985) 
X 
De ontdekking van de spermatozoa van de mens wordt vaak ten onrechte 
toegeschreven aan Anthonie van Leeuwenhoek in plaats van aan de 
medisch student Johan Ham (1651-1725). 
(J-W.J. Lammers, Ned Tijdsch Geneeek 118: 784-788, 1974) 
XI 
Patiënt, behandelend specialist en geconsulteerde specialist zijn ge-
baat bij vroegtijdige aanvraag van pre-operatieve behandelingsadvie-
zen. 
XII 
De Koninklijke Nederlandse Lawn Tennis Bond zal de speelvreugde van 
menig tennisspeler verhogen door te voorkomen dat competitiewedstrij-
den op wisselende baansoorten gespeeld moeten worden. 
XIII 
Nakaarten na een brldgespel wordt vaak ten onrechte aangegrepen als 
een gelegenheid om de eigen partner te overtroeven. 
J-W.J. Lammers 18 april 1986 



